

CITATION REPORT

List of articles citing

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

DOI: 10.1002/1097-0142(19850715)56:23.O.co;2-x
Cancer, 1985, 56, 403-12.

Source: <https://exaly.com/paper-pdf/17684440/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1100	Epithelial Neoplasia of the Endometrium in Pregnancy. A Case Report. 1987 , 73, 175-180		8
1099	Uterine corpus and uterine cancer. 1988 , 12, 65-129		4
1098	Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone. 1988 , 154, 335-41		76
1097	Cytologic criteria of hyperplastic lesions in endometrial samples obtained by the endocyte sampler. 1988 , 4, 283-7		8
1096	Cellularity of the Ovarian Stroma in Patients with Endometrial Carcinoma. 1989 , 75, 289-291		1
1095	Patterns of reactivity with the monoclonal antibodies HMFG1 and HMFG2 in normal endometrium, endometrial hyperplasia and adenocarcinoma. 1989 , 15, 179-86		2
1094	The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. 1989 , 160, 126-31		186
1093	A comparative morphometric and cytophotometric study of endometrial hyperplasia, atypical hyperplasia, and endometrial carcinoma. 1989 , 20, 219-23		19
1092	Proliferative changes in the genital tissue of female mice during the oestrous cycle. 1990 , 23, 619-35		11
1091	Endometrial hyperplasia: value of endometrial thickness in ultrasonographic diagnosis and clinical significance. 1990 , 18, 173-7		29
1090	Vaginosonography for early detection of endometrial carcinoma?. 1990 , 335, 1569-71		182
1089	Regulation of epidermal growth factor and insulin-like growth factor I receptors by estradiol and progesterone in normal and neoplastic endometrial cell cultures. 1990 , 38, 396-406		35
1088	Value of immunohistochemical demonstration of several epithelial markers in hyperplastic and neoplastic endometrium. 1990 , 37, 346-53		13
1087	Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. 1991 , 13, 297-311		35
1086	Expression of carcinoembryonic antigen and ferritin in normal, hyperplastic, and neoplastic endometrium. 1991 , 41, 193-8		5
1085	Pathology of the uterine corpus. 1991 , 22, 776-91		29
1084	Risks and benefits of replacement estrogen. 1992 , 43, 239-51		48

1083	Hormone replacement and cancer. 1992 , 48, 345-55		37
1082	Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. 1992 , 188, 856-9		61
1081	Microcarcinoma of the Endometrium: A Mapping Study with Special Reference to Cytologic Atypia in the Endometrium. 1992 ,		
1080	Oestrogen and progesterone receptor immunocytochemistry in human hyperplastic and neoplastic endometrium. 1992 , 166, 171-7		19
1079	Inhibin (10.7 kD prostatic peptide) in normal, hyperplastic, and malignant human endometria: an immunohistochemical study. 1992 , 168, 35-40		13
1078	Immunocytodiagnosis of atypical hyperplasia and endometrial carcinoma in post-menopausal women. 1992 , 51, 869-72		3
1077	CA 125 and CA 19-9 immunolocalization in normal, hyperplastic, and carcinomatous endometrium. <i>Cancer</i> , 1993 , 71, 2551-6	6.4	12
1076	Immunohistochemical study of p53 expression in endometrial carcinomas: correlation with markers of proliferating cells and clinicopathologic features. 1993 , 3, 363-368		11
1075	Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. 1993 , 423, 265-71		44
1074	Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. 1993 , 169, 690-4		52
1073	Indications for hysterectomy. 1993 , 328, 856-60		258
1072	Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. 1993 , 60, 672-4		24
1071	The menopause: health implications and clinical management. 1993 , 41, 426-36		87
1070	An evaluation of the Gynochek for endometrial sampling. 1993 , 13, 198-200		
1069	Sequential observation of spontaneous endometrial adenocarcinoma development in Donryu rats. 1994 , 22, 261-9		48
1068	Endometrial Carcinoma. 1994 , 439-486		56
1067	Pathology of endometrium treated with tamoxifen. 1994 , 47, 827-33		150
1066	Microsatellite instability in sporadic endometrial carcinoma. 1994 , 86, 1216-21		170

1065	[Myometrium and endometrium. Histopathologic aspects of benign lesions]. 1994 , 255 Suppl 2, S350-5		1
1064	The additional prognostic value of morphometric nuclear arrangement and DNA-ploidy to other morphometric and stereologic features in endometrial hyperplasias. 1994 , 4, 289-297		13
1063	Postmenopausal endometrial hyperplasia: role of danazol therapy. 1994 , 44, 155-9		10
1062	Women and cancer. 1994 , 46, 195-202		
1061	Aspects of hormone replacement therapy. 1994 , 734, 271-84		7
1060	Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? UK Continuous Combined HRT Study Investigators. 1994 , 344, 979-82		65
1059	Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. 1994 , 20, 191-8		28
1058	Endometrial hyperplasia. 1994 , 1, 151-157		
1057	Very low estrogen-desogestrel contraceptive in perimenopausal hormonal replacement. 1994 , 18, 93-103		4
1056	Stromal-epithelial communications in hyperplastic human endometrium. 1994 , 170, 1061-70; discussion 1070-2		7
1055	Flow-cytometric analysis of nuclear DNA content in endometrial adenocarcinoma. Atypical mitoses are associated with DNA aneuploidy. 1994 , 102, 341-8		8
1054	Treatment of precursors of endometrial cancer. 1994 , 37, 130-4		8
1053	Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy. <i>Cancer</i> , 1995 , 76, 2044-52	6.4	33
1052	Clinical aspects of risk in women with endometrial carcinoma. 1995 , 23, 131-6		13
1051	The role of computerized morphometric and cytometric feature analysis in endometrial hyperplasia and cancer prognosis. 1995 , 23, 137-46		13
1050	Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. 1995 , 23, 160-4		38
1049	Endometrial hyperplasia and the risk of carcinoma. 1995 , 5, 233-235		85
1048	Endometrial Hyperplasia and Epithelial Cytoplasmic Change. 1995 , 160-183		1

1047	Combined continuous hormone replacement therapy: a critical review. 1995 , 86, 306-16	92
1046	Localized endometrial proliferations associated with pregnancy: clinical and histopathologic features of 11 cases. 1995 , 26, 1233-40	8
1045	Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. 1995 , 26, 1260-7	251
1044	Risk of endometrial hyperplasia progressing to cancer. 1995 , 172, 1320	
1043	Endometrial carcinoma. 1996 , 335, 640-9	440
1042	Ultrastructure of the microvasculature in human endometrial hyperplasia. 1996 , 174, 174-83	7
1041	Chronological observation of mouse endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17 beta-estradiol. 1996 , 104, 115-9	7
1040	Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. 1996 , 23, 235-9	14
1039	Endometrial response in estrogen replacement therapy quarterly combined with a progestogen. 1996 , 24, 63-71	19
1038	Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed oestrogen use. 1996 , 24, 21-30	11
1037	Diagnostic accuracy of hysteroscopy in endometrial hyperplasia. 1996 , 25, 187-91	36
1036	The uterus and the menopause. 1996 , 10, 419-32	1
1035	HRT and the Endometrium. 1996 , 2, 23-25	
1034	DNA ploidy, cell cycle kinetics, and low versus high grade atypia in endometrial hyperplasia. 1996 , 106, 22-8	4
1033	Déclaration de principe Directives cliniques sur l'hystérectomie. 1996 , 18, 688-699	
1032	Policy Statement Clinical Practice Guidelines for Hysterectomy. 1996 , 18, 677-687	
1031	Flow cytometric DNA analysis of abnormal endometrium. 1996 , 178, 199-202	2
1030	Diagnostic efficacy of endometrial cytology with the Abradul cell sampler supplemented by laser scanning confocal microscopy. 1996 , 40, 277-82	6

1029	Study on the long-term follow-up of endometrial hyperplasia. 1996 , 1, 163-169	11
1028	Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. 1996 , 174, 1518-21	71
1027	Differential diagnosis of abnormal uterine bleeding. 1996 , 175, 766-9	93
1026	Molecular events in endometrial carcinogenesis. 1996 , 6, 425-438	20
1025	Trials of improved care for the elderly. 1996 , 334, 665; author reply 666	
1024	Screening for Prostate Cancer. 1996 , 334, 666-668	11
1023	Polycystic ovary syndrome. 1996 , 334, 668	1
1022	Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group. 1996 , 334, 668-9	52
1021	Disability payments among schizophrenic cocaine abusers. 1996 , 334, 664; author reply 665	3
1020	Treatment of androgen excess in females: yesterday, today and tomorrow. 1997 , 11, 411-33	7
1019	Precancerous lesions of the endometrium and medical treatment. 1997 , 2, 239-41	3
1018	Combined continuous hormone replacement therapy: an update. 1997 , 6, 1-22	
1017	Office procedures. Endometrial biopsy. 1997 , 24, 303-26	6
1016	Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data. 1997 , 65, 102-14	26
1015	Effects of drugs on the endometrium: recent advances. 1997 , 4, 121-127	3
1014	Diagnosis and management of endometrial hyperplasia. 1997 , 7, 8-15	1
1013	Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. 1997 , 90, 434-40	329
1012	The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. 1997 , 23, 223-30	70

1011	Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy? Menopause Study Group (United States, Italy, Netherlands, Switzerland, Belgium, Germany, and Finland. 1997 , 177, 1178-83	26
1010	Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. 1997 , 67, 295-302	12
1009	Early triple malignancies of the female genital tract: A case report. 1997 , 2, 51-54	5
1008	Die diagnostische Hysteroskopie – ein neuer Standard. 1997 , 30, 384-391	1
1007	Endometrial cancer. 1997 , 21, 65-127	24
1006	Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. <i>Cancer</i> , 1997 , 79, 320-7	6.4 215
1005	Flow cytometric cell cycle kinetics and quantitative measurement of c-erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrial biopsies. 1997 , 30, 209-14	9
1004	Endometrial cytology in postmenopausal hormone replacement therapy. 1998 , 19, 161-7	2
1003	Endometrial intraepithelial carcinoma diagnosed by brush cytology and p53 immunostaining, and confirmed by hysterectomy. 1998 , 19, 284-7	9
1002	GnRH agonists and add-back therapy: is there a perfect combination?. 1998 , 105, 475-85	44
1001	The PTEN, BAX, and IGF1R genes are mutated in endometrial atypical hyperplasia. 1998 , 89, 985-90	32
1000	Endometrial carcinoma after endometrial ablation: high-risk factors predicting its occurrence. 1998 , 179, 569-72	60
999	Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. 1998 , 178, 1087-99	56
998	Endometrial adenocarcinoma following the conservative treatment of an atypical polypoid adenomyoma. 1998 , 3, 400-402	3
997	Successful transfer of frozen embryos in a woman with complex atypical endometrial hyperplasia after medical treatment. 1998 , 62, 289-290	
996	Endometrial histopathological findings in Sri Lankan women with postmenopausal bleeding. 1998 , 62, 295-296	
995	Transvaginal ultrasonographic evaluation of the endometrium related to the histological findings in pre- and perimenopausal women. 1998 , 45, 199-204	9
994	Postmenopausal endometrial pathologies with tamoxifen treatment: comparison between hysteroscopic and hysterectomy findings. 1999 , 48, 187-92	11

993	Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. 1999 , 14, 479-84	17
992	Endocrine cancer risks for women during the perimenopause and beyond. 1999 , 17, 359-70	2
991	Nucleolar organizer regions in differentiated preneoplastic and neoplastic endometrial lesions. 1999 , 47, 205-9	2
990	Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium. 1999 , 72, 138-42	25
989	Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. 1999 , 73, 299-304	42
988	Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. 1999 , 73, 126-36	31
987	[Algorithm of endometrial meta- and hyperplasia]. 1999 , 20, 56-62	3
986	Diagnostik des Endometriumkarzinomes und seiner Präkanzerosen. 1999 , 5, 381-387	
985	Operative Therapie des Endometriumkarzinoms und seiner Präkanzerosen. 1999 , 5, 403-409	
984	An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. 1999 , 181, 525-9	123
983	Endometrial resection: a diagnostic tool in postmenopausal women. 1999 , 8, 111-114	1
982	Loss of expression of the gene deleted in colon carcinoma (DCC) is closely related to histologic differentiation and lymph node metastasis in endometrial carcinoma. <i>Cancer</i> , 1999 , 85, 453-64	6.4 20
981	Complications of Hormone Treatment. 1999 , 265-288	
980	Hysteroscopic resection of endometrial hyperplasia. 1999 , 6, 151-4	9
979	Expression of nm23 in normal, hyperplastic and neoplastic endometrial tissues. 1999 , 195, 829-34	1
978	Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate). 1999 , 32, 41-50	6
977	Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. 1999 , 32, 161-70	69
976	HRT and cancer risk: separating fact from fiction. 1999 , 33 Suppl 1, S65-72	6

975	Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. 1999 , 93, 594-8	21
974	Prognostic factors relating to survival in uterine endometrioid carcinoma. 1999 , 66, 155-62	21
973	Screening for gynecologic cancer. 1999 , 83, 1467-87	5
972	hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. 1999 , 155, 1767-72	260
971	Risk Factors for Endometrial Hyperplasia and Cancer Among Women With Abnormal Bleeding. 1999 , 93, 594-598	6
970	Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. 2000 , 18, 3459-63	88
969	PROGESTINS IN HORMONE REPLACEMENT THERAPY: IMPACT ON ENDOMETRIAL AND BREAST CANCER. 2000 , 22, 677-681	
968	Norethindrone Acetate and Estradiol-Induced Endometrial Hyperplasia. 2000 , 96, 373-379	
967	Problems of endometrial histology interpretation. 2000 , 3, 288-93	
966	Introduction to the ISGYP Symposium on Endometrial Hyperplasia. 2000 , 19, 299-300	1
965	The molecular biology of endometrial tumorigenesis: does it have a message?. 2000 , 19, 310-3	13
964	Endometrial hyperplasia: is it time for a quantum leap to a new classification?. 2000 , 19, 314-21	45
963	Performance characteristics of the Indiana University Medical Center endometrial sampler (Tao Brush) in an outpatient office setting, first year's outcomes: recognizing histological patterns in cytology preparations of endometrial brushings. 2000 , 22, 186-95	14
962	Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. 2000 , 190, 462-9	143
961	Theories of endometrial carcinogenesis: a multidisciplinary approach. 2000 , 13, 295-308	386
960	The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. 2000 , 107, 1392-400	74
959	Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. 2000 , 76, 287-90	230
958	Intratumoral genetic heterogeneity and progression of endometrioid type endometrial adenocarcinomas. 2000 , 78, 152-7	24

957	Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. 2000 , 79, 18-22	116
956	The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. 2000 , 79, 424-9	50
955	Tratamento Clínico e Seguimento das Hiperplasias de Endométrio. 2000 , 22, 325-331	1
954	Diagnosis of endometrial cancer and its precursors. 2000 , 20, 27-40	6
953	Hormonal interactions in endometrial cancer. 2000 , 7, 227-42	132
952	Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. 2000 , 13, 309-27	117
951	Which is the appropriate hormone replacement therapy after sub-total hysterectomy?. 2000 , 3, 65-7	
950	Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. 2000 , 53, 697-703	50
949	Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization. 2000 , 156, 1827-33	31
948	A diagnostic approach to endometrial biopsies: selected topics. 2000 , 6, 13-20	3
947	The prognostic value and clinical utility of estrogen and progesterone receptors in endometrial carcinoma. 2000 , 7, 55-59	2
946	Norethindrone acetate and estradiol-induced endometrial hyperplasia. 2000 , 96, 373-9	44
945	Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. 2001 , 76, 25-31	95
944	Atypical endometrial hyperplasia shares genomic abnormalities with endometrioid carcinoma by comparative genomic hybridization. 2001 , 32, 615-22	17
943	Endometrial hyperplasia. 2001 , 11, 160-163	
942	Ultrasonographic and morphological studies of the postmenopausal endometrium using unopposed estrogen replacement therapy with regular pause: a prospective preliminary study. 2001 , 98, 119-23	1
941	Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. 2001 , 167, 39-48	208
940	Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. 2001 , 98, 325-31	48

939	Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. 2001 , 25, 930-5	64
938	A double-blind randomized study on the effects of red clover isoflavones on the endometrium. 2001 , 8, 338-46	46
937	The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. 2001 , 8, 245-51	39
936	Clinical value of dilatation and curettage for abnormal uterine bleeding. 2001 , 264, 174-6	6
935	Natural history of endometrial hyperplasia. Study of 77 patients. 2001 , 265, 85-8	25
934	Hormonale Kontrazeption, Hormonsubstitution und reproduktives Krebsrisiko. 2001 , 17, 87-99	
933	Endometriosis-associated invasive adenocarcinoma involving the rectum in a postmenopausal female: report of a case. 2001 , 44, 1530-3	21
932	Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. 2001 , 54, 399-404	54
931	Current molecular aspects of the carcinogenesis of the uterine endometrium. 2001 , 11, 339-48	74
930	Suppressed gap junctional intercellular communication in carcinogenesis of endometrium. 2001 , 93, 317-23	38
929	Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur. 2001 , 32, 295-301	17
928	Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. 2001 , 80, 181-8	87
927	Production of activin A in hyperplasia and adenocarcinoma of the human endometrium. 2001 , 83, 31-8	18
926	beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. 2001 , 84, 209-17	129
925	Alteration of CD44 and cadherins expression: possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. 2001 , 438, 78-85	49
924	Prognostic aspects on endometrial hyperplasia and neoplasia. 2001 , 439, 118-26	24
923	Design and conduct of clinical trials in hormone replacement therapy. 2001 , 943, 89-108	6
922	Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. 2001 , 27, 222-4	409

921	An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. 2001 , 184, 70-5	71
920	Ultrasound, hysteroscopy and endometrial biopsy in the investigation of endometrial cancer. 2001 , 15, 381-91	25
919	Optimal management of endometrial hyperplasia. 2001 , 15, 393-405	43
918	Hysteroscopic and immunohistochemical findings in endometrial lesions unresponsive to medroxyprogesterone acetate: a report on four cases. 2001 , 10, 183-191	1
917	Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. 2001 , 115, 32-8	90
916	Ultrasound and Menstrual History in Predicting Endometrial Hyperplasia in Polycystic Ovary Syndrome. 2001 , 98, 325-331	30
915	Imaging the endometrium: disease and normal variants. 2001 , 21, 1409-24	157
914	Gynecologic Malignancies in the Elderly. 2001 , 834-844	
913	The menopause and its treatment in perspective. 2001 , 77, 292-304	16
912	Hormone replacement therapy and the endometrium. 2001 , 54, 435-40	64
911	Karzinomrisiko endometrialer Hyperplasien: Eine kliniko-pathologische Analyse von 538 Fällen. 2001 , 61, 501-506	3
910	Präkanzeröse Läsionen des Endometriums: Aspekte der molekularen Pathogenese und Probleme der Nomenklatur. 2001 , 61, 8-14	8
909	Spectrum of endometrial hyperplasia and its mimics on saline hysterosonography. 2002 , 179, 385-9	10
908	[Precancerous lesion of the endometrium and endometrial morphology in patients with tamoxifen therapy]. 2002 , 124, 3-9	
907	Tenascin expression in normal, hyperplastic, and neoplastic endometrium. 2002 , 21, 161-6	9
906	Hystfektomie. 2002 , 24, 49-61	3
905	PTEN mutations and evolving concepts in endometrial neoplasia. 2002 , 14, 59-65	46
904	Estradiol-induced hyperplasia in endometrial biopsies from women on hormone replacement therapy. 2002 , 26, 1269-75	10

903	Menorrhagia. 221-244	
902	. 2002 , 4, 173-192	3
901	Hysterectomy. 2002 , 24, 37-48	34
900	Development of a miniature, low-dose, frameless intrauterine levonorgestrel-releasing system for contraception and treatment: a review of initial clinical experience. 2002 , 4, 71-82	7
899	Administración transdérmica combinada continua de estradiol-acetato de noretindrona frente a estradiol solo en mujeres menopáusicas. 2002 , 29, 133-142	
898	The search for the ideal SERM. 2002 , 3, 681-91	27
897	Atypical complex endometrial hyperplasia treated with the Gynelase system. 2002 , 9, 73-8	5
896	Resectoscopic surgery in women with abnormal uterine bleeding and nonatypical endometrial hyperplasia. 2002 , 9, 131-7	8
895	Resectoscopic surgery in 10 women with abnormal uterine bleeding and atypical endometrial hyperplasia. 2002 , 9, 138-44	8
894	[Effect of estrogens and antiestrogens on the endometrium]. 2002 , 30, 933-7	12
893	Endometrial safety of hormone replacement therapy: review of literature. 2002 , 42, 93-104	32
892	The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer. 2002 , 43, 77-85	31
891	HRT and cancer risks. 2002 , 43 Suppl 1, S35-52	9
890	Risk of finding an endometrial cancer when atypical hyperplasia was incidentally diagnosed on hysteroscopic resection products. 2002 , 103, 58-9	12
889	Genetic alterations in endometrial hyperplasia and cancer. 2002 , 175, 205-11	18
888	Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. 2002 , 179, 79-86	71
887	Gynecologic problems of the perimenopause: evaluation and treatment. 2002 , 29, 455-73	7
886	Freqüência de Adenocarcinoma de Endométrio em Ambulatório de Histeroscopia: Um Estudo Multicêntrico. 2002 , 24, 45-50	1

885	Histologic diagnosis of endometrial hyperplasia. 2002 , 441, 306-7	5
884	Age-dependent differences in tumor cell polarity in endometrial carcinomas. 2002 , 128, 205-13	4
883	Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia. 2002 , 35, 9-15	30
882	The value of curettage in diagnosis of endometrial hyperplasia. 2002 , 84, 135-9	23
881	Epithelial abnormalities in cystic ovarian endometriosis. 2002 , 84, 280-4	75
880	Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. 2002 , 86, 62-8	23
879	Atypical endometrial hyperplasia in an 18-year-old woman. 2003 , 267, 252-5	2
878	Histopathologie und Stadieneinteilung des Endometriumkarzinoms und seiner Präkanzerosen. 2003 , 9, 1211-1218	1
877	Die Früherkennung des Endometriumkarzinoms. 2003 , 9, 1202-1210	
876	How representative are Pipelle endometrial biopsies? A retrospective analysis of 324 biopsies followed by transcervical resection of the endometrium or hysterectomy. 2003 , 6, 277-281	6
875	Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium. 2003 , 53, 846-52	9
874	Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. 2003 , 188, 927-31	201
873	Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. 2003 , 91, 526-33	75
872	Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer. 2003 , 88, 108-17	57
871	Endometrial hyperplasia with secretory changes. 2003 , 88, 386-93	15
870	Preparing for the unexpected: encountering gynecological problems when operating for colon cancer. 2003 , 60, 12-16	1
869	Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody. 2003 , 13, 42-6	8
868	Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. 2003 , 80, 1234-40	75

867	Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. 2003 , 80, 1315-24	100
866	Hormone replacement therapy and endometrial, ovarian and colorectal cancer. 2003 , 17, 139-47	57
865	Proliferative mucinous lesions of the endometrium: analysis of existing criteria for diagnosing carcinoma in biopsies and curettings. 2003 , 11, 261-70	39
864	Transvaginal color Doppler ultrasonography for prediction of pre-cancerous endometrial lesions. 2003 , 80, 299-306	14
863	Clinical over- and under-estimation in patients who underwent hysterectomy for atypical endometrial hyperplasia diagnosed by endometrial biopsy: the predictive value of clinical parameters and diagnostic imaging. 2003 , 108, 213-6	22
862	Cost-effectiveness of the use of transvaginal sonography in the evaluation of postmenopausal bleeding. 2003 , 45, 275-82	33
861	Detection of endometrial intraepithelial neoplasia (EIN) in postmenopausal endometrium. 2003 , 46, 153-61	4
860	Hormonal management of early endometrial cancer. 2003 , 10, 105-109	
859	Classification of microhysteroscopic images and their correlation with histologic diagnoses. 2003 , 10, 233-46	23
858	[Atypical hyperplasia of endometrium and hysteroscopy]. 2003 , 31, 355-8	3
857	Ultrasound, hysteroscopy and endometrial biopsy in the investigation of endometrial cancer. 2003 , 3, 11-15	2
856	The classification, diagnosis and management of endometrial hyperplasia. 2003 , 3, 89-97	7
855	Should endometrial hyperplasia be regarded as a reason for abnormal uterine bleeding in users of the intrauterine contraceptive device?. 2003 , 8, 17-20	3
854	Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. 2003 , 17, 405-7	56
853	Atypical endometrial hyperplasia: grounds for possible misdiagnosis of endometrial adenocarcinoma. 2003 , 56, 163-7	27
852	Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma. 2003 , 14, 220-6	40
851	Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis. 2003 , 22, 115-22	5
850	Guides to an efficient search for the best evidence. 2003 , 21, 5-8	

849	Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. 2003 , 22, 141-8	33
848	Biomarkers in diagnostic obstetric and gynecologic pathology: a review. 2003 , 10, 55-68	45
847	Can colour Doppler ultrasonography predict the prognosis of endometrial hyperplasia?. 2003 , 23, 282-4	2
846	Assessment of Abnormal Bleeding in Menopausal Women: An Update. 2003 , 9, 117-122	
845	Simple hyperplasia versus proliferative endometrium: stereological study. 2003 , 39, 73-79	
844	Epidemiology of Uterine Corpus Cancers. 2004 , 188-207	1
843	Endometrial cancer: prevention, screening, and early detection. 2004 , 293-310	
842	Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. 2004 , 14, 348-353	35
841	Management of Early-Stage Endometrial Cancer. 2004 , 259-273	1
840	Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. 2004 , 57, 840-4	27
839	Endometrial adenocarcinoma in situ in complex atypical hyperplasia: correlation with findings in subsequent hysterectomy specimen. 2004 , 12, 225-30	15
838	Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study. 2004 , 58, 42-8	11
837	Diffuse cystic endometrial hyperplasia and metastatic endometrial adenocarcinoma in a vietnamese pot-bellied pig (<i>Sus scrofa</i>). 2004 , 16, 587-9	19
836	Coexisting endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia. 2004 , 30, 205-9	39
835	Management of postmenopausal bleeding in Sweden: a need for increased use of hydrososonography and hysteroscopy. 2004 , 83, 89-95	18
834	Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. 2004 , 14, 348-53	100
833	H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. 2004 , 14, 521-5	46
832	Overexpression of estrogen receptor-alpha gene suppresses gap junctional intercellular communication in endometrial carcinoma cells. 2004 , 23, 1109-16	23

831	Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma. 2004 , 92, 116-26	8
830	Involution of PTEN-null endometrial glands with progestin therapy. 2004 , 92, 1008-13	45
829	Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. 2004 , 93, 92-7	26
828	Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development: a population-based study from northern Norway with long-term follow-up. 2004 , 95, 82-8	10
827	Bias associated with delayed verification in test accuracy studies: accuracy of tests for endometrial hyperplasia may be much higher than we think!. 2004 , 2, 18	5
826	Managing women with post-menopausal bleeding. 2004 , 18, 125-43	42
825	Focus on endometrial and cervical cancer. 2004 , 5, 533-8	93
824	Neoplasia of the female reproductive tract: effects of hormone therapy. 2004 , 24, 259-63	15
823	Correlation between the DNA global methylation status and progesterone receptor expression in normal endometrium, endometrioid adenocarcinoma and precursors. 2004 , 445, 129-34	38
822	Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors. 2004 , 109, 317-21	47
821	Current controversies about combined hormone therapy and the relative risks to the breast and endometrium. 2004 , 7, 229-37	
820	Cancer of the endometrium: current aspects of diagnostics and treatment. 2004 , 2, 24	33
819	Endometrial hyperplasia. 2004 , 14, 99-103	20
818	[Conservative treatment of endometrial cancer and atypical hyperplasia]. 2004 , 32, 433-41	5
817	Insights into future diagnosis and treatment of women with common gynecologic cancers. 2004 , 6, 101-102	
816	Management of endometrial polyps: a clinical review. 2004 , 4, 1-6	8
815	Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia. 2004 , 48, 125-32	15
814	Phyto-oestrogens and the endometrium. 2004 , 364, 2081-2	5

813	Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma. 2004 , 23, 18-25	16
812	Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. 2004 , CD000402	16
811	Insights into future diagnosis and treatment of women with common gynecologic cancers. 2004 , 6, 101-102	
810	Endometrial hyperplasia: a review. 2004 , 59, 368-78	111
809	Enhanced detection of atypical hyperplasia in endometrial polyps by PTEN expression. 2004 , 12, 36-9	9
808	Polypoid endometriosis: a clinicopathologic analysis of 24 cases and a review of the literature. 2004 , 28, 285-97	151
807	Differences in serum bisphenol a concentrations in premenopausal normal women and women with endometrial hyperplasia. 2004 , 51, 595-600	96
806	Saline infusion sonohysterography: technique, indications, and imaging findings. 2004 , 23, 97-112; quiz 114-5	297
805	Endometrial Hyperplasia. 2005 , 25, 1-5	
804	Endometrial carcinoma after endometrial resection for dysfunctional uterine bleeding. 2005 , 106, 1174-6	6
803	Hysteroscopy and menopause: past and future. 2005 , 17, 366-75	13
802	Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. 2005 , 105, 779-87	40
801	Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?. 2005 , 15, 420-5	4
800	Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. 2005 , 15, 537-41	35
799	Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. 2005 , 31, 98-106	13
798	Orphan nuclear receptor DAX-1 in human endometrium and its disorders. 2005 , 96, 645-52	18
797	Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. 2005 , 18, 324-30	98
796	Which surgical procedure for patients with atypical endometrial hyperplasia?. 2005 , 15, 127-31	18

795	Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. 2005 , 97, 740-50		44
794	Endometrial cancer in young, normal-weight women. 2005 , 99, 388-92		59
793	Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. 2005 , 99, 472-6		16
792	Study on the morphology and reproducibility of the diagnosis of endometrial lesions utilizing liquid-based cytology. <i>Cancer</i> , 2005 , 105, 56-64	6.4	53
791	The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. <i>Cancer</i> , 2005 , 103, 2304-12	6.4	147
790	Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps. 2005 , 272, 59-66		15
789	Endometriose. 2005 , 495-510		
788	Fertility-sparing surgery for malignancies in women. 2005 , 43-7		72
787	EIN and WHO94. 2005 , 58, 1-6		84
786	Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. 2005 , 23, 188-95		12
785	Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women. 2005 , 20, 336-42		11
784	Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. 2005 , 14, 1724-31		71
783	Treatment of non-atypic endometrial hyperplasia using thermal balloon endometrial ablation therapy. 2005 , 59, 202-6		8
782	Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. 2005 , 11, 8258-64		36
781	Incidencia de adenocarcinoma de endometrio en la pieza de histerectomía tras diagnóstico de hiperplasia endometrial atípica. 2005 , 32, 194-199		
780	Accuracy of hysteroscopic diagnosis of endometrial hyperplasia: a retrospective study of 323 patients. 2005 , 12, 247-53		32
779	Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. 2005 , 36, 555-61		48
778	Gynecological health of females with congenital heart disease. 2005 , 98, 379-87		36

777	Endometrial cancer--surprising reports. 2005 , 51, 329-33	2
776	Magnetic resonance spectroscopy of premalignant and malignant endometrial disorders: a feasibility of in vivo study. 2005 , 118, 241-5	25
775	Genetic imbalances in endometrial hyperplasia and endometrioid carcinoma detected by comparative genomic hybridization. 2005 , 120, 107-14	13
774	Can flowcytometric DNA studies forecast the prognosis of endometrial hyperplasia?. 2005 , 122, 104-6	1
773	Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. 2005 , 122, 107-11	33
772	Endometrial hyperplasia/adenocarcinoma. a conventional approach. 2005 , 9, 174-81	34
771	Long term hormone therapy for perimenopausal and postmenopausal women. 2005 , CD004143	57
770	Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. 2005 , 12, 227-33	95
769	Diagnosis of Endometrial Biopsies and Curettings. 2005 ,	17
768	Prevalence and clinical predictors of endometrial hyperplasiain anovulatory women presenting with amenorrhea. 2006 , 22, 101-5	25
767	[Endometrial hyperplasia: A review]. 2006 , 35, 542-50	8
766	Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. 2006 , 108, 1-11	16
765	[Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey]. 2006 , 34, 27-33	12
764	The management of endometrial hyperplasia: an evaluation of current practice. 2006 , 125, 259-64	58
763	Management of endometrial cancer. 2006 , 32, 838-43	26
762	Endometrial Cancer. 2006 ,	
761	GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma. 2006 , 14, 187-92	16
760	Precursors of endometrial clear cell carcinoma. 2006 , 30, 1519-30	58

759	CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. 2006 , 16 Suppl 1, 448-51		10
758	Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. 2006 , 16 Suppl 1, 452-7		14
757	Lack of pericryptal fibroblastic cells adjacent to intestinal epithelial metaplastic gastric glands. 2006 , 48, 610-2		
756	Atypical polypoid adenomyoma: a systematic review of the English literature. 2006 , 48, 609-10		69
755	Is resectoscopic treatment of atypical endometrial polyps a safe option?. 2006 , 195, 1328-30		6
754	Estrogenic effects of a methanol extract of the fruit of <i>Brenania brieyi</i> de Wild (Rubiaceae). 2006 , 61, 86-89		1
753	Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer. 2006 , 101, 269-73		13
752	Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. 2006 , 101, 214-23		73
751	The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. 2006 , 101, 470-5		100
750	Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. 2006 , 101, 331-41		202
749	Endometrial glandular and stromal breakdown, part 1: cytomorphological appearance. 2006 , 34, 609-13		30
748	Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. <i>Cancer</i> , 2006 , 106, 87-94	6.4	233
747	Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. <i>Cancer</i> , 2006 , 106, 804-11	6.4	203
746	Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. <i>Cancer</i> , 2006 , 106, 812-9	6.4	415
745	Problems with the current diagnostic approach to complex atypical endometrial hyperplasia. <i>Cancer</i> , 2006 , 106, 729-31	6.4	18
744	Cellular features of endometrial hyperplasia and well differentiated adenocarcinoma using the Endocyte sampler: Diagnostic criteria based on the cytoarchitecture of tissue fragments. <i>Cancer</i> , 2006 , 108, 77-85	6.4	50
743	Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. 2006 , 12, 6373-8		106
742	The granulatin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. 2006 , 13, 304-11		18

741	My approach to the interpretation of endometrial biopsies and curettings. 2006 , 59, 801-12	80
740	PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. 2006 , 12, 5932-5	180
739	Progesterone receptor modulators and the endometrium: changes and consequences. 2007 , 13, 567-80	65
738	Common gynecologic problems in geriatric-aged women. 2007 , 50, 687-708	6
737	Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. 2007 , 26, 103-14	108
736	Cancer de l'endomÈtre. 2007 , 2, 1-4	
735	Unopposed estradiol therapy in postmenopausal women: results from two randomized trials. 2007 , 109, 581-7	18
734	Operative treatment of endometrial hyperplasia in kidney graft recipients: report of seven cases. 2007 , 39, 2756-8	1
733	Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women. 2007 , 11, 103-8	34
732	Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. 2007 , 11, 297-311	82
731	Sex hormone-binding globulin expression in the endometria of women with polycystic ovary syndrome. 2007 , 87, 321-8	14
730	Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. 2007 , 57, 210-3	65
729	Valor de la histeroscopia en la hiperplasia endometrial con atipias. 2007 , 50, 23-30	1
728	Endometrial carcinoma. 2007 , 2, 57-85	170
727	Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. 2007 , 25, 2798-803	291
726	Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. 2007 , 34, 717-37, ix	31
725	Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. 2007 , 14, 68-73	20
724	Endometrial hyperplasia. 2007 , 17, 169-172	4

723	Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer. 2007 , 125-146		
722	Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. 2007 , 120, 821-4		139
721	Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort. <i>Cancer</i> , 2007 , 109, 1303-11	6.4	36
720	Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. 2007 , 17, 233-41		57
719	Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. 2007 , 17, 905-13		25
718	Endometrial hyperplasia involving endometrial polyps: report of a series and discussion of the significance in an endometrial biopsy specimen. 2007 , 114, 944-50		27
717	Deregulation of tissue homeostasis in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. 2007 , 104, 290-5		32
716	B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. 2007 , 106, 119-27		91
715	Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. 2007 , 106, 325-33		119
714	Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. 2007 , 196, 243.e1-5		85
713	Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. 2007 , 196, 247.e1-5		37
712	The accuracy of frozen pathology at time of hysterectomy in patients with complex atypical hyperplasia on preoperative biopsy. 2007 , 196, e40-2		36
711	Discussion: 'Accuracy of preoperative endometrial sampling' by Huang et al. 2007 , 196, e1-6		1
710	Prognosefaktoren und Prognose des Endometriumkarzinoms. 2007 , 40, 27-33		
709	The modern management of endometrial cancer. 2007 , 1, 103-119		8
708	Prävention des Endometriumkarzinoms. 2008 , 41, 508-512		4
707	Conservative management of patients with early endometrial carcinoma: a systematic review. 2008 , 10, 155-62		20
706	Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia. 2008 , 22, 73-7		8

705	The endometrial hyperplasias revisited. 2008 , 453, 223-31	10
704	Transcription factor Egr1 acts as an upstream regulator of beta-catenin signalling through up-regulation of TCF4 and p300 expression during trans-differentiation of endometrial carcinoma cells. 2008 , 216, 521-32	25
703	Pathology of uterine malignancies. 2008 , 20, 433-47	17
702	Endometrial hyperplasia. 2008 , 10, 211-216	9
701	The ability of endometrial biopsies with atypical complex hyperplasia to guide surgical management. 2008 , 199, 69.e1-4	10
700	Resectoscopic treatment of atypical endometrial polyps in fertile women. 2008 , 199, 365.e1-3	5
699	Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. 2008 , 18, 146-51	18
698	Expression of receptor-binding cancer antigen expressed on SiSo cells and estrogen receptor subtypes in the normal, hyperplastic, and carcinomatous endometrium. 2008 , 18, 152-8	0
697	Frequent inactivation of RUNX3 in endometrial carcinoma. 2008 , 110, 439-44	13
696	Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. 2008 , 111, 68-73	79
695	Endometrial Glandular Dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. 2008 , 3, 6	28
694	Endometrial cancer: multiplexed Luminex approaches for early detection. 2008 , 2, 527-37	5
693	Current issues in the management of endometrial cancer. 2008 , 83, 97-112	105
692	Postmenopausal Bleeding. 2008 , 3, 391-397	
691	Sonohysterography: Technique and Clinical Applications. 2008 , 3, 427-449	9
690	Innovative Endocrinology of Cancer. 2008 ,	5
689	Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. 2008 , 39, 866-74	43
688	Heparanase expression increases throughout the endometrial hyperplasia-cancer sequence. 2008 , 101, 166-71	5

687	Expression of aquaporin-1 in normal, hyperplasic, and carcinomatous endometria. 2008 , 101, 239-44	25
686	In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia. 2008 , 110, 163-9	21
685	Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. 2008 , 90, 2006.e5-8	10
684	The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. 2008 , 139, 169-75	95
683	Cáncer de endometrio. 2008 , 12, 1-4	
682	[Epidemiology of menometrorrhagia]. 2008 , 37 Suppl 8, S307-16	7
681	[Methods and efficacy of medical and surgical treatment of non functional menorrhagia]. 2008 , 37 Suppl 8, S368-83	4
680	Management of dysfunctional uterine bleeding. 2008 , 35, 219-34, viii	11
679	Invited Commentary: Endometrial Hyperplasia--Getting Back to Normal. 2008 , 168, 571-574	11
678	Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. 2008 , 98, 45-53	80
677	Selected Background Findings and Interpretation of Common Lesions in the Female Reproductive System in Macaques. 2008 , 36, 142s-163s	48
676	Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history. 2008 , 168, 563-70; discussion 571-6	74
675	Epplein et al. Respond to Endometrial Hyperplasia--Getting Back to Normal. 2008 , 168, 575-576	
674	Management of endometrial cancer. 2008 , 4, 479-89	4
673	Significance of concurrent endometrial cancer in women with a preoperative diagnosis of atypical endometrial hyperplasia. 2008 , 30, 896-901	23
672	Endometrial effects of tibolone in elderly, osteoporotic women. 2008 , 112, 653-9	17
671	Immunohistochemical markers in endometrial hyperplasia: is there a panel with promise? A review. 2008 , 16, 329-43	18
670	From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. 2008 , 17, 133-8	60

669	Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings. 2008 , 27, 45-8	29
668	Endometrial cancer. 2008 , 111, 436-47	161
667	Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. 2008 , 20, 20-5	30
666	Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device. 2008 , 15, 1002-4	25
665	Diagnosing endometrial hyperplasia: why is it so difficult to agree?. 2008 , 32, 691-8	66
664	Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. 2008 , 27, 318-25	29
663	Body of the uterus. 267-277	
662	Uterus. 2009 , 1295-1340	1
661	The Role of PTEN Mutation in the Development of Endometrial Carcinoma. 2009 , 45, 47	
660	RAD001 (Everolimus) Can prevent tamoxifen-related endometrial and stromal hyperplasia. 2009 , 19, 375-9	7
659	. 2009 ,	0
658	The endometrium--from estrogens alone to TSECs. 2009 , 12, 463-77	12
657	Neoplasia. 2009 , 63-86	
656	Biological significance of prolactin in gynecologic cancers. 2009 , 69, 5226-33	71
655	Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. 2009 , 8, 2126-35	28
654	Long term hormone therapy for perimenopausal and postmenopausal women. 2009 , CD004143	46
653	Biological behavior of preneoplastic conditions of the endometrium: A retrospective 16-year study in south India. 2009 , 30, 131-5	4
652	Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. 2009 , 15, 5772-83	69

651	Adrenomedullin, Bcl-2 and microvessel density in normal, hyperplastic and neoplastic endometrium. 2009 , 59, 530-6	15
650	Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. 2009 , 114, 383-9	110
649	Cancer issues. 2009 , 23, 87-107	9
648	Abnormal uterine and post-menopausal bleeding in the acute gynaecology unit. 2009 , 23, 595-607	21
647	Incidence of endometrial hyperplasia. 2009 , 200, 678.e1-6	100
646	Oviduct-specific glycoprotein is a molecular marker for invasion in endometrial tumorigenesis identified using a relevant mouse model. 2009 , 124, 1349-57	7
645	The diagnosis of endometrial hyperplasia on curettage: how reliable is it?. 2009 , 279, 489-92	12
644	[Endometrial carcinomas and precursor lesions--new aspects]. 2009 , 30, 261-7	
643	Presence of endometrial adenocarcinoma in situ in complex atypical endometrial hyperplasia is associated with increased incidence of endometrial carcinoma in subsequent hysterectomy. 2009 , 22, 37-42	30
642	Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. 2009 , 22, 699-708	30
641	The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. 2009 , 49, 316-22	34
640	Endometrial hyperplasia and the risk of progression to carcinoma. 2009 , 63, 39-44	91
639	Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy. 2009 , 19, 1-7	8
638	Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction. 2009 , 88, 1234-42	6
637	Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. 2009 , 4, 41	43
636	Diagnosis and Management of Polycystic Ovary Syndrome. 2009 ,	0
635	The evaluation of anosognosia in stroke patients. 2009 , 27, 280-9	42
634	The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. 2009 , 25, 683-91	35

633	Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome. 2009 , 115, 102-107	35
632	Validez de la histeroscopia y de la biopsia endometrial en el diagnóstico diferencial de las hiperplasias. 2009 , 52, 378-385	1
631	Delayed Diagnosis After Atypical Glandular Cells on Cervical Cytology. 2009 , 13, 237-243	6
630	Progestin therapy of complex endometrial hyperplasia with and without atypia. 2009 , 113, 655-662	46
629	Endometrial Hyperplasia and Endometrial Cancer. 53-66	
628	Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. 2009 , CD000402	41
627	Low-grade endometrial adenocarcinoma: a diagnostic algorithm for distinguishing atypical endometrial hyperplasia and other benign (and malignant) mimics. 2009 , 16, 1-22	30
626	Pathologie tumorale endométriale bénigne et lésions frontalières de l'endomètre. 2010 , 5, 1-15	
625	Uterine adenocarcinoma with prominent desmoplasia in a geriatric miniature pig. 2010 , 72, 253-6	5
624	Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. 2010 , 89, 1438-46	19
623	Precursors of endometrial and ovarian carcinoma. 2010 , 456, 1-12	24
622	Endokrine Therapie des Endometriumkarzinoms und seiner Präkanzerosen. 2010 , 8, 17-25	
621	Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. 2010 , 17, 844-50	14
620	Lymph node dissection in the surgical management of atypical endometrial hyperplasia. 2010 , 202, 176.e1-4	16
619	Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk. 2010 , 203, 349.e1-6	37
618	Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. 2010 , 203, 547.e1-10	137
617	PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma. 2010 , 119, 516-9	21
616	Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluorescence in situ hybridization. 2010 , 118, 97-104	1

615	APC promoter hypermethylation is an early event in endometrial tumorigenesis. 2010 , 101, 321-7	33
614	Mouse models of uterine corpus tumors: clinical significance and utility. 2010 , 2, 882-905	11
613	Comparison of WHO and endometrial intraepithelial neoplasia classifications in predicting the presence of coexistent malignancy in endometrial hyperplasia. 2010 , 21, 97-101	59
612	HIPERPLASIA ENDOMETRIAL: ANÁLISIS DE SERIE DE CASOS DIAGNOSTICADOS EN BIOPSIA ENDOMETRIAL. 2010 , 75,	0
611	The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma. 2010 , 21, 50-5	7
610	The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. 2010 , 21, 102-5	23
609	Current concepts in the pathology and epigenetics of endometrial carcinoma. 2010 , 42, 613-7	15
608	Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/- mice. 2010 , 3, 1246-58	19
607	NAC1, a potential stem cell pluripotency factor expression in normal endometrium, endometrial hyperplasia and endometrial carcinoma. 2010 , 36, 1097-103	17
606	Hereditary Colorectal Cancer. 2010 ,	
605	Characterization and comparison of precursors of ovarian and endometrial carcinoma: parts I and II. 2010 , 18, 181S-189S	9
604	Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. 2010 , 28, 788-92	176
603	Loss of inhibitory insulin receptor substrate-1 phosphorylation: An early event in endometrial hyperplasia and progression to carcinoma. 2010 , 9, 2698-9	7
602	Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy. 2010 , 116, 365-373	55
601	Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma. 2010 , 3, 290-300	20
600	Endometrial hyperplasia: a clinician's review. 2010 , 20, 116-120	9
599	Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena) treatment of endometrial hyperplasia: an immunohistochemical study. 2010 , 89, 393-8	14
598	Premenopausal bleeding: When should the endometrium be investigated?--A retrospective non-comparative study of 3006 women. 2010 , 148, 86-9	25

597	Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia. 2010 , 150, 80-3	27
596	Microsatellite instability in endometrial polyps. 2010 , 153, 193-7	5
595	Hallazgos histeroscópicos en mujeres asintomáticas con ecografía sugestiva de patología endometrial. 2010 , 53, 495-501	2
594	Endometrial hyperplasia. 2010 , 27, 199-214	32
593	Endometrial intraepithelial neoplasia. 2010 , 27, 215-25	30
592	Female Reproductive System. 2010 , 597-700	
591	Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. 2010 , 13, 228-37	35
590	Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. 2011 , 72, 10-4	31
589	Atypical Endometrial Hyperplasia and Well Differentiated Endometrioid Adenocarcinoma of the Uterine Corpus. 2011 , 4, 149-98	4
588	The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. 2011 , 18, 75-80	25
587	Clinical Approach to Diagnosis and Management of Endometrial Hyperplasia and Carcinoma. 2011 , 4, 113-30	1
586	Endometrial cancer, types, prognosis, female hormones and antihormones. 2011 , 14, 418-25	22
585	Selected Topics in the Molecular Pathology of Endometrial Carcinoma. 2011 , 4, 131-47	1
584	The pathogenesis of endometrial carcinomas at menopause: facts and figures. 2011 , 64, 553-60	23
583	Current management of endometrial hyperplasia-a survey of United Kingdom consultant gynaecologists. 2011 , 158, 305-7	19
582	Endometrial hyperplasia - the dilemma of management remains: a retrospective observational study of 280 women. 2011 , 159, 172-5	21
581	Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. 2011 , 159, 176-9	16
580	The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. 2011 , 68, 189-96	48

579	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. 2011 , 12, 38-48	138
578	Activated leukocyte cell adhesion molecule expression is up-regulated in the development of endometrioid carcinoma. 2011 , 21, 523-8	6
577	Progression of pelvic implants to complex atypical endometrial hyperplasia after uterine morcellation. 2011 , 117, 447-449	30
576	Diagnosis of abnormal uterine bleeding with imaging. 2011 , 18, 421-4	6
575	Endometrial Clear Cell Carcinoma. 2011 , 16, 108-114	2
574	ENDOMETRIAL CANCER. 2011 , 173-197	
573	Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. 2011 ,	1
572	Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. 2011 , 80, 181-92	16
571	[Precursor lesions of endometrial carcinoma: diagnostic approach and molecular pathology]. 2011 , 32 Suppl 2, 255-64	11
570	Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. 2011 , 129, 1237-43	35
569	Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. 2011 , 12, 447-57	34
568	Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006). 2011 , 41, 817-9	10
567	Expression of HOXA10 in endometrial hyperplasia and adenocarcinoma and regulation by sex hormones in vitro. 2011 , 21, 800-5	4
566	Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. 2011 , 93, 356-67	52
565	Conservative management of young patients with endometrial highly-differentiated adenocarcinoma. 2011 , 31, 13-7	18
564	Ten problematical issues identified by pathology review for multidisciplinary gynaecological oncology meetings. 2012 , 65, 293-301	27
563	Endometrial intraepithelial neoplasia terminology in practice: 4-year experience at a single institution. 2012 , 31, 160-165	8
562	Pathology of endometrioid carcinoma. 2012 , 99, 7-12	14

561	Conservative Management of Atypical Hyperplasia and Grade I Endometrial Carcinoma: Review of the Literature and Presentation of a Series. 2012 , 28, 262-269	7
560	The genomics and genetics of endometrial cancer. 2012 , 2012, 33-47	79
559	Risk for advanced-stage endometrial cancer in surgical specimens from patients with complex endometrial hyperplasia with atypia. 2012 , 73, 38-42	12
558	PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia. 2012 , 31, 151-159	29
557	[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]. 2012 , 99, 479-98	1
556	Pure compared with mixed serous endometrial carcinoma: two different entities?. 2012 , 120, 1371-81	26
555	Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. 2012 , 36, 1683-90	52
554	Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. 2012 , 67, 726-33	15
553	Endometrial cancer. 2012 , 120, 383-97	221
552	Endometrial carcinoma precursors: hyperplasia and endometrial intraepithelial neoplasia. 110-126	
551	Hysteroscopic inspection and total curettage are insufficient for discriminating endometrial cancer from atypical endometrial hyperplasia. 2012 , 228, 365-70	16
550	Predicting the coexistence of an endometrial adenocarcinoma in the presence of atypical complex hyperplasia: immunohistochemical analysis of endometrial samples. 2012 , 22, 1264-72	15
549	Reproducibility of endometrial intraepithelial neoplasia diagnosis is good, but influenced by the diagnostic style of pathologists. 2012 , 25, 877-84	23
548	Loss of RKIP expression during the carcinogenic evolution of endometrial cancer. 2012 , 65, 122-8	21
547	Cancer of the corpus uteri. 2012 , 119 Suppl 2, S110-7	32
546	Endometrial cancer. 2012 , 39, 255-68	37
545	Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer. 2012 , 121-139.e6	4
544	Long term hormone therapy for perimenopausal and postmenopausal women. 2012 , CD004143	102

543	Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. 2012 , CD000402	58
542	Hiperplasia endometrial atípica en biopsia preoperatoria y resultado de la pieza de histerectomía. 2012 , 39, 196-198	
541	Diagnosis and management of endometrial hyperplasia. 2012 , 19, 562-71	71
540	Contemporary quality of life issues affecting gynecologic cancer survivors. 2012 , 26, 169-94	34
539	Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls. 2012 , 23, 120-4	34
538	c-Kit proto-oncogene expression in endometrial hyperplasia and endometrial cancer. 2012 , 286, 197-200	10
537	Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. 2012 , 207, 36.e1-8	36
536	Screening for uterine tumours. 2012 , 26, 257-66	49
535	Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. 2012 , 124, 542-8	34
534	Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. 2012 , 125, 263-70	89
533	Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group study. 2012 , 125, 129-35	5
532	Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. 2012 , 125, 124-8	43
531	Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. 2012 , 125, 536-40	43
530	Management of Gynecological Cancers in Older Women. 2013 ,	1
529	Conservative treatment of early endometrial cancer. 2013 , 228, 1154-8	19
528	LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. 2013 , 28, 2966-71	52
527	Demystifying endometrial hyperplasia. 2013 , 19, 223-230	1
526	Cancer de l'endométrie : actualités. 2013 , 2013, 49-53	0

525	Erkrankungen des Endometriums. 2013 , 329-403		0
524	Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. 2013 , 29, 156-9		16
523	Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. 2013 , 34, 171-208		246
522	Histopathologic assessment of the entire endometrium in asymptomatic women. 2013 , 44, 2293-301		10
521	Evaluaci3n morfol3gica endometrial histerosc3pica. 2013 , 56, 79-85		
520	Predictive ability of estrogen receptor (ER), progesterone receptor (PR), COX-2, Mlh1, and Bcl-2 expressions for regression and relapse of endometrial hyperplasia treated with LNG-IUS: a prospective cohort study. 2013 , 130, 58-63		12
519	Endometrial hyperplasia: a clinicopathological study in a tertiary care hospital. 2013 , 63, 394-8		5
518	Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. 2013 , 28, 1231-6		38
517	Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium. 2013 , 31, 500-4		6
516	Critical tumor suppressor function mediated by epithelial Mig-6 in endometrial cancer. 2013 , 73, 5090-9		23
515	Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. 2013 , 37, 1342-8		62
514	Ultrasonographic endometrial thickness measurement is predictive for treatment response in simple endometrial hyperplasia without atypia. 2013 , 14, 19-22		3
513	Feasibility of RNA and DNA extraction from fresh pipelle and archival endometrial tissues for use in gene expression and SNP arrays. 2013 , 2013, 576842		19
512	Bariatric surgery and endometrial pathology in asymptomatic morbidly obese women: a prospective, pilot study. 2013 , 120, 795-800		32
511	Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. <i>Cancer</i> , 2013 , 119, 3027-33	6.4	24
510	Investigation and management of abnormal peri-menopausal bleeding. 2013 , 19, 147-54		3
509	Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. 2013 , 121, 1172-1180		37
508	Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. 2013 , 121, 1165-1171		50

507	Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. 2013 , CD009458	9
506	The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. 2013 , 23, 288-93	35
505	The role of liquid-based preparation in the evaluation of endometrial cytology. 2013 , 57, 423-35	27
504	Coexisting carcinoma in endometrial hyperplasia: does more risk factor mean better discrimination?. 2013 , 24, 1-2	
503	Risk factor analysis of coexisting endometrial carcinoma in patients with endometrial hyperplasia: a retrospective observational study of Taiwanese Gynecologic Oncology Group. 2013 , 24, 14-20	13
502	LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. 2013 , 24, 128-34	28
501	Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. 2013 , 56, 67-75	26
500	[Indications and methods of hysterectomy]. 2014 , 155, 1152-7	2
499	Cyclin D1 G870A Polymorphism is Associated with an Increased Risk of Simple Endometrial Hyperplasia in Egyptian Women. 2014 , 03,	1
498	Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer. 2014 , 5, 9783-97	25
497	MRI of the Female Genitourinary Tract. 2014 , 221-240	4
496	Transforming growth factor β signaling in uterine development and function. 2014 , 5, 52	40
495	Fertility-sparing treatment in a young patient with complex atypical hyperplasia of the endometrium. 2014 , 6, 30-32	
494	Combined colonoscopy and endometrial biopsy cancer screening results in women with Lynch syndrome. 2014 , 135, 85-9	14
493	DNA methylation as a biomarker for the detection of hidden carcinoma in endometrial atypical hyperplasia. 2014 , 135, 552-9	25
492	Endometrial intraepithelial neoplasia. 2014 , 138, 484-91	54
491	Treatment of simple and complex endometrial non-atypical hyperplasia with natural progesterone: response rate to different doses. 2014 , 30, 899-901	3
490	Hyperplasia and carcinoma in secretory endometrium: a diagnostic challenge. 2014 , 33, 107-13	9

489	High prevalence of atypical hyperplasia in the endometrium of patients with epithelial ovarian cancer. 2014 , 142, 213-21	5
488	Molecular Pathogenesis of Uterine Serous Carcinoma. 2014 , 3, 33-39	
487	Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. 2014 , 290, 83-6	7
486	Uterine epithelial cell proliferation and endometrial hyperplasia: evidence from a mouse model. 2014 , 20, 776-86	31
485	Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. 2014 , 133, 33-7	41
484	Reproducibility of current classifications of endometrial endometrioid glandular proliferations: further evidence supporting a simplified classification. 2014 , 64, 284-92	30
483	Proceedings of the 2013 National Toxicology Program Satellite Symposium. 2014 , 42, 12-44	4
482	Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. 2014 , 121, 477-86	70
481	Fertility sparing surgery in gynecologic cancer. 2014 , 64, 234-8	3
480	Hormone receptor expression patterns in the endometrium of asymptomatic morbidly obese women before and after bariatric surgery. 2014 , 133, 78-82	23
479	Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group. 2014 , 179, 147-52	6
478	A 45-year-old woman with heavy vaginal bleeding. 1-3	
477	A 42-year-old woman with irregular bleeding. 52-54	
476	Diagnosis and Management of Endometrial Hyperplasia. 2014 , 34, 5-6	
475	Diagnosis and Management of Endometrial Hyperplasia. 2014 , 34, 1-5	
474	Joint Effect of Genotypic and Phenotypic Features of Reproductive Factors on Endometrial Cancer Risk. 2015 , 5, 15582	8
473	Confronting the challenges of the menopausal transition. 2015 , 1, 7	
472	Practice Bulletin No. 149: Endometrial cancer. 2015 , 125, 1006-1026	135

471	Management of Endometrial Hyperplasia: A Survey of Members of the Korean Gynecologic Oncology Group. 2015 , 25, 1277-84	4
470	Management of cancer of the body of the uterus. 360-373	
469	[Uterine neoplasia in two geriatric miniature pet pigs - diagnostics and therapy. Two case reports]. 2015 , 43, 427-33	1
468	The Role of Frozen-Section in the Surgical Management of Patients with Endometrial Intraepithelial Neoplasia. 2015 , 31, 181-7	2
467	Antioxidant Status and Sex Hormones in Women with Simple Endometrial Hyperplasia. 2015 ,	
466	Genistein reduces angiogenesis and apoptosis in women with endometrial hyperplasia. 2015 , 27	2
465	Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies. 2015 , 128, 153-80	11
464	Cancer of the corpus uteri. 2015 , 131 Suppl 2, S96-104	56
463	Cãncer de endometrio. 2015 , 19, 1-8	
462	Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. 2015 , 139, 419-23	28
461	Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia. 2015 , 22, 758-66	8
460	Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. 2015 , 20, 270-8	58
459	Environmental chemical exposure may contribute to uterine cancer development: studies with tetrabromobisphenol A. 2015 , 43, 464-73	41
458	A novel preoperative scoring system for predicting endometrial cancer in patients with complex atypical endometrial hyperplasia and accuracy of frozen section pathological examination in this context: a multicenter study. 2015 , 79, 50-6	6
457	Supervised clustering of immunohistochemical markers to distinguish atypical and non-atypical endometrial hyperplasia. 2015 , 31, 282-5	5
456	Comparison of diagnostic accuracy between endometrial curettage and pipelle aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group Study (KGOG 2019). 2015 , 45, 980-2	4
455	Association of glutathione-S-transferase P1 (GSTP1)-313 A>G gene polymorphism and susceptibility to endometrial hyperplasia among Egyptian women. 2015 , 16, 361-365	1
454	Phytoestrogen genistein inhibits EGFR/PI3K/NF-kB activation and induces apoptosis in human endometrial hyperplasia cells. 2015 , 5, 56075-56085	16

453	Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. 2015 , 213, 469-78	51
452	OB-GYN Pathology for the Clinician. 2015 ,	
451	Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. 2015 , 131, 234-9	24
450	Ambulatory hysteroscopy and its role in the management of abnormal uterine bleeding. 2015 , 41, 284-91	4
449	Pathology of Endometrial Hyperplasia and Carcinoma. 2015 , 105-121	
448	Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. 2015 , 139, 261-7	32
447	Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. 2015 , 139, 424-8	38
446	Surgical management of abnormal uterine bleeding in fertile age women. 2015 , 11, 513-25	7
445	Overexpression of Fli-1 is associated with adverse prognosis of endometrial cancer. 2015 , 33, 469-75	6
444	Concurrent endometrial intraepithelial carcinoma (EIC) and endometrial hyperplasia. 2015 , 2, 1-4	0
443	Endometrial pathology in the postmenopausal woman [An evidence based approach to management. 2015 , 17, 29-38	14
442	Long-term clinical outcomes following resectoscopic endometrial ablation of non-atypical endometrial hyperplasia in women with abnormal uterine bleeding. 2015 , 22, 66-77	12
441	The association of the microcystic, elongated and fragmented (MELF) invasion pattern in endometrial carcinomas with deep myometrial invasion, lymphovascular space invasion and lymph node metastasis. 2015 , 35, 397-402	21
440	Perimenopausal bleeding: Patterns, pathology, response to progestins and clinical outcome. 2015 , 35, 517-21	6
439	Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. 2015 , 20, 782-9	7
438	Vaginal hysterectomy for uterovaginal prolapse: what is the incidence of concurrent gynecological malignancy?. 2015 , 26, 421-5	15
437	Endometrial pathology in postmenopausal women with no bleeding. 2015 , 18, 241-5	11
436	Therapeutic options for management of endometrial hyperplasia. 2016 , 27, e8	88

435	Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study. 2016 , 26, 711-5	11
434	Transvaginal ultrasound examination of the endometrium in postmenopausal women without vaginal bleeding. 2016 , 48, 390-6	13
433	Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway. 2016 , 107, 1806-1817	40
432	GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma. 2016 , 32, 141-7	2
431	New concepts for an old problem: the diagnosis of endometrial hyperplasia. 2017 , 23, 232-254	120
430	Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients With Lynch Syndrome. 2016 , 40, 1177-91	19
429	The diagnosis of endometrial atypia by hysteroscopy with guided biopsy in postmenopausal patients with hyperplasia: a reliable practice?. 2016 , 13, 515-519	
428	Atypical Endometrial Polyps and Concurrent Endometrial Cancer: A Systematic Review. 2016 , 128, 519-525	18
427	Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response. 2016 , 143, 650-654	7
426	Metformin for endometrial hyperplasia: a Cochrane protocol. 2016 , 6, e013385	1
425	Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma. 2016 , 76, 170-175	10
424	Sampling in Atypical Endometrial Hyperplasia: Which Method Results in the Lowest Underestimation of Endometrial Cancer? A Systematic Review and Meta-analysis. 2016 , 23, 692-701	25
423	A high dose mode of action for tetrabromobisphenol A-induced uterine adenocarcinomas in Wistar Han rats: A critical evaluation of key events in an adverse outcome pathway framework. 2016 , 77, 143-59	11
422	Differential Expression of IR-A, IR-B and IGF-1R in Endometrial Physiology and Distinct Signature in Adenocarcinoma. 2016 , 101, 2883-91	22
421	Metformin for endometrial hyperplasia. 2016 ,	2
420	[Pitfalls in the histopathological diagnostics of endometrial carcinoma and its precursors : Clinically relevant differential diagnoses, avoidance of false positive diagnoses]. 2016 , 37, 512-520	
419	Through thick and thin: a pictorial review of the endometrium. 2016 , 41, 2312-2329	8
418	HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia. 2016 , 115, 725-30	9

417	Long-term risk of endometrial cancer following postmenopausal bleeding and reassuring endometrial biopsy. 2016 , 95, 1418-1424	10
416	Risk of coexisting endometrial carcinoma in case of atypical endometrial hyperplasia diagnosed on total hysteroscopic resection. 2016 , 203, 210-3	7
415	Cancer de l'endométrie induit : quelle place pour l'échographie ?. 2016 , 26, 55-65	1
414	Risk of endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia treated with total laparoscopic hysterectomy. 2016 , 5, 69-73	5
413	Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. 2016 , 14, 2	30
412	Paired boxed gene 1 expression: A single potential biomarker for differentiating endometrial lesions associated with favorable outcomes in patients with endometrial carcinoma. 2016 , 42, 1159-67	3
411	Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. 2016 , 123, 1512-9	24
410	Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. 2016 , 140, 152-60	11
409	Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. 2016 , 214, 689.e1-689.e17	71
408	Precancerous Lesions of the Gynecologic Tract. 2016 ,	2
407	Endometrial Cancer. 2016 , 1203-1229.e7	4
406	Premalignant disease in the genital tract in pregnancy. 2016 , 33, 33-43	6
405	SPAG9 May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin. 2016 , 81, 267-74	4
404	Micronucleus testing as a cancer detector: endometrial hyperplasia to carcinoma. 2016 , 293, 1065-71	8
403	The importance of age and menopausal status in endometrial complex hyperplasia with atypia. 2016 , 36, 102-5	1
402	Levels of Regulatory Proteins Associated With Cell Proliferation in Endometria From Untreated Patients Having Polycystic Ovarian Syndrome With and Without Endometrial Hyperplasia. 2016 , 23, 211-8	9
401	Long-term hormone therapy for perimenopausal and postmenopausal women. 2017 , 1, CD004143	110
400	The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions. 2017 , 37, 58-63	7

399	Role of diffusion weighted MRI in the differential diagnosis of endometrial cancer, polyp, hyperplasia, and physiological thickening. 2017 , 41, 86-94	23
398	[Fertility-sparing management of endometrial cancer and atypical hyperplasia]. 2017 , 45, 112-118	4
397	Endometrial Cancer. 2017 , 1-15	
396	Diagnostic accuracy of endometrial biopsy in relation to the amount of tissue. 2017 , 70, 941-946	9
395	Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis. 2017 , 24, 1322-1329	25
394	Molecular profiles of benign and (pre)malignant endometrial lesions. 2017 , 38, 329-335	17
393	The anorectic agent, lorcaserin, disturbs estrous cyclicity and produces endometrial hyperplasia without affecting ovarian population in female rats. 2017 , 183, 69-77	5
392	Current strategies in the diagnosis of endometrial cancer. 2017 , 296, 5-14	7
391	Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. 2017 ,	1
390	Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. 2017 , 26, 368-373	12
389	Metformin for endometrial hyperplasia. 2017 , 10, CD012214	11
388	[Histological and molecular classification of endometrial carcinoma and therapeutical implications]. 2017 , 104, 1001-1012	7
387	Frequency of endometrial cancer and atypical hyperplasia in infertile women undergoing hysteroscopic polypectomy. 2017 , 43, 1465-1471	10
386	Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. 2017 , 67, 69-77	22
385	The regulation of Hh/Gli1 signaling cascade involves Gsk3 β -mediated mechanism in estrogen-derived endometrial hyperplasia. 2017 , 7, 6557	13
384	KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance. 2017 , 7, 6765	65
383	Sexuality and Fertility. 2017 , 359-378	
382	Pathology and Molecular Pathology of Uterine and Ovarian Cancers. 2017 , 247-278	

- 381 Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: a clinicopathological study of 238 cases. **2017**, 59, 120-124 15
- 380 Abnormal Uterine Bleeding Is Associated With Increased BMP7 Expression in Human Endometrium. **2017**, 24, 671-681 7
- 379 Fertility outcomes in infertile women with complex hyperplasia or complex atypical hyperplasia who received progestin therapy and in vitro fertilization. **2017**, 18, 1022-1025 7
- 378 The Management of Endometrial Hyperplasia and Carcinoma in Primary Care. 210-219
- 377 Aktuelle Aspekte zur Diagnostik und Therapie des Endometriumkarzinoms. **2017**, 38, 111-117
- 376 New classification system of endometrial hyperplasia WHO 2014 and its clinical implications. **2017**, 16, 107-111 28
- 375 Intrauterine levonorgestrel delivery with frameless fibrous delivery system: review of clinical experience. **2017**, 9, 49-58 7
- 374 The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. **2018**, 223, 108-112 10
- 373 Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia?. **2018**, 53, 350-353 6
- 372 Uterine Corpus Cancer. **2018**, 268-287
- 371 Neoplasia. **2018**, 71-97 4
- 370 The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia. **2018**, 148, 485-490 15
- 369 Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and hysterectomy during the following 9-14 years. **2018**, 222, 171-175 5
- 368 RNA sequencing reveals significant miRNAs in Atypical endometrial hyperplasia. **2018**, 225, 129-135 2
- 367 Endometrial hyperplasia: recent updates and clinicopathological correlation. **2018**, 27, 199-204
- 366 Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance. **2018**, 31, 1291-1301 17
- 365 Routine histologic features in complex atypical hyperplasia can predict the presence of endometrial carcinoma: a clinicopathological study of 222 cases. **2018**, 80, 40-46 5
- 364 Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer. **2018**, 105-120.e6

363 Focus on Gynecologic Malignancies. **2018**,

362 MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells. **2018**, 37, 255-262 7

361 Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer. **2018**, 44, 151-156 26

360 Management of Endometrial Cancer Precursors in Obese Women. **2018**, 189-212

359 Diagnostic value of histopathological examination results obtained during screening of patients with diagnosed atypical hyperplasia. **2018**, 17, 144-148

358 Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. **2018**, 1

357 Precursors of Endometrial Carcinoma. **2018**, 1-34

356 Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria. **2019**, 17, 532-538 6

355 Cancer of the corpus uteri. **2018**, 143 Suppl 2, 37-50 166

354 Sonic hedgehog protects endometrial hyperplasia cells against oxidative stress via suppressing mitochondrial fission protein dynamin-like GTPase (Drp1). **2018**, 129, 582-599 12

353 Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. **2018**, 97, 1415-1426 28

352 Preinvasive Endometrial Neoplasia. **2018**, 524-555 0

351 Adenocarcinoma, Carcinosarcoma, and Other Epithelial Tumors of the Endometrium. **2018**, 582-651

350 Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing. **2018**, 214, 1231-1233 0

349 No. 109-Hysterectomy. **2018**, 40, e567-e579 4

348 Uterus-Hormonal Regulation. **2018**, 305-311

347 N 109 - Hystéctomie. **2018**, 40, e581-e595

346 MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. **2018**, 18, 605 4

345	Hypoxia is involved in the reduction of HtrA3 in patients with endometrial hyperplasia and cancer. 2018 , 503, 2918-2923	8
344	Expression of PAX2 and PTEN in Oestrogen-Driven Endometrial Hyperplasia and Neoplasia. 2019 , 17, 1	
343	miRNAs as Candidate Biomarker for the Accurate Detection of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neoplasia. 2019 , 9, 526	7
342	Usefulness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and background endometrium of sporadic endometrial cancer cases. 2019 , 45, 2037-2042	5
341	Benign and Premalignant Lesions of the Endometrium. 2019 , 12, 315-328	4
340	Selective vs Complete Sampling in Hysterectomy Specimens Performed for Atypical Hyperplasia. 2019 , 152, 666-674	1
339	Endometrial Precancers. 2019 , 425-454	
338	Precursors of Endometrial Carcinoma. 2019 , 439-472	2
337	G-protein coupled receptor 64 (GPR64) acts as a tumor suppressor in endometrial cancer. 2019 , 19, 810	7
336	Significant risk of occult cancer in complex non-atypical endometrial hyperplasia. 2019 , 300, 1147-1154	20
335	Intrauterine Progestin Therapy as a New Approach to Premalignant Endometrial Polyps: A Prospective Observational Study. 2019 , 39, 4897-4903	2
334	Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia. 2019 , 299, 801-808	10
333	[Precursor lesions of endometrial carcinoma]. 2019 , 40, 13-20	3
332	Atypical Endometrial Hyperplasia Arising in a Cesarean Section Scar: A Mechanism of Malignant Transformation. 2019 , 12, 317-321	
331	Non-Ionizing Radiation Created by Mobile Phone Progresses Endometrial Hyperplasia: An Experimental Rat Study. 2019 , 50, 36-43	5
330	Endometrial Hyperplasia: Diagnosis and Management. 2019 , 25-43	
329	New perspectives on screening and early detection of endometrial cancer. 2019 , 145, 3194-3206	21
328	Is there any difference between endometrial hyperplasia and endometrial carcinoma in terms of expression of TRPM2 and TRPM7 ion channels?. 2019 , 49, 653-660	2

327	Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. 2019 , 30, e49	5
326	PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. 2019 , 299, 1511-1524	30
325	Long-term effect of pregnancy-related factors on the development of endometrial neoplasia: A nationwide retrospective cohort study. 2019 , 14, e0214600	4
324	Preventive Effects by Black Raspberries of Endometrial Carcinoma Initiation and Promotion Induced by a High-Fat Diet. 2019 , 63, e1900013	1
323	Molecular expression characteristics confirm the malignancy concealed by morphological alterations in endometrial cancer after fertility-preserving treatment. 2019 , 299, 1673-1682	4
322	Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. 2019 , 127, 427-434	28
321	Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. 2019 , 299, 1233-1242	34
320	[S3 guidelines on the diagnosis and treatment of carcinoma of the endometrium : Requirements for pathology]. 2019 , 40, 21-35	1
319	HISTOPATHOLOGIC FINDINGS IN WOMEN UNDERGOING HYSTEROSCOPIC RESECTION OF ENDOMETRIAL POLYPS AND UTERINE MYOMAS. 2019 , 58, 627-631	0
318	Expression of Cyclin D1 in normal and hyperplastic endometrium. 2019 , 8, 4474	
317	A prospective study of comparison between transvaginal sonogram and histopathological examination in perimenopausal women with abnormal uterine bleeding. 2019 , 8, 4233	
316	Endometrial Cancer. 2019 , 1-16	
315	[Current recommendations for surveillance, risk reduction and therapy in Lynch syndrome patients]. 2019 , 57, 1309-1320	10
314	Expression: A Potential Metabolic Biomarker to Differentiate Endometrial Precancer and Cancer That Is Associated with Poor Outcomes in Endometrial Carcinoma. 2019 , 16,	6
313	Guideline No. 390-Classification and Management of Endometrial Hyperplasia. 2019 , 41, 1789-1800	22
312	Directive clinique N° 392-Classification et prise en charge de l'hyperplasie de l'endomètre. 2019 , 41, 1801-1813	
311	Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. 2019 , 30, e57	32
310	Challenges and controversies in the conservative management of uterine and ovarian cancer. 2019 , 55, 93-108	6

309	Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study. 2019 , 126, 936-943	6
308	Precursors of Endometrial Carcinoma. 2019 , 225-259	1
307	A20-mediated deubiquitination of ER α in the microenvironment of CD163 macrophages sensitizes endometrial cancer cells to estrogen. 2019 , 442, 137-147	5
306	Gene Promoter Methylation in Endometrial Carcinogenesis. 2019 , 25, 659-667	5
305	Retrospective characterization of reproductive tract lesions in relation to age, parity, and contraception in captive suidae and tayassuidae. 2019 , 127, 137-144	4
304	Oncofertility: What can we do from bench to bedside?. 2019 , 442, 148-160	6
303	Molecular Genetics of Endometrial Carcinoma. 2019 , 14, 339-367	79
302	The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. 2019 , 144, 641-650	56
301	BCL-2 and PAX2 Expressions in EIN which Had Been Previously Diagnosed as Non-Atypical Hyperplasia. 2019 , 25, 471-476	4
300	Histopathology and Clinical Outcomes of 151 Women with Postmenopausal Bleeding Treated with Resectoscopic Surgery. 2020 , 27, 763-773	6
299	Long-term outcome of postmenopausal women with non-atypical endometrial hyperplasia on endometrial sampling. 2020 , 55, 546-551	4
298	Congruence Between 1994 WHO Classification of Endometrial Hyperplasia and Endometrial Intraepithelial Neoplasia System. 2020 , 153, 40-48	22
297	Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy. 2020 , 235, 1339-1348	11
296	Hysteroscopic Photodynamic Diagnosis Using 5-Aminolevulinic Acid: A High-Sensitivity Diagnostic Method for Uterine Endometrial Malignant Diseases. 2020 , 27, 1087-1094	2
295	A Diagnostic Approach to Endometrial Cytology by Means of Liquid-Based Preparations. 2020 , 64, 195-207	10
294	The most important discoveries of the past 50 years in gynaecological pathology. 2020 , 76, 6-10	3
293	Uterine Cancer. 2020 , 1508-1524.e4	2
292	Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma. 2020 , 39, 19-25	2

291 An Introduction to Hysteroscopy. **2020**, 1-5

290 Diagnostic Hysteroscopy: Accuracy and Interpretation of Findings. **2020**, 36-56

289 Research and New Developments in Hysteroscopy. **2020**, 235-248

288 Analgesia and Anaesthesia for Hysteroscopy. **2020**, 72-82

287 Hysteroscopic Electrosurgery. **2020**, 96-108

286 Hysteroscopic Sterilisation. **2020**, 158-166

285 Hysteroscopic Management of Uterine Adhesions. **2020**, 180-192

1

284 Audit, Data Collection and Clinical Governance in Hysteroscopy. **2020**, 204-221

283 Training in Hysteroscopic Skills. **2020**, 222-234

282 Atypical Endometrial Hyperplasia and Unexpected Cancers at Final Histology: A Study on Endometrial Sampling Methods and Risk Factors. **2020**, 10,

10

281 Simultaneous FTIR and Raman Spectroscopy in Endometrial Atypical Hyperplasia and Cancer. **2020**, 21,

6

280 Index. **2020**, 249-258

279 Effects of melatonin on uterine hypertrophy/hyperplasia: A preliminary experimental rat study. **2020**, 6, e05142

0

278 Management of Congenital Uterine and Vaginal Anomalies. **2020**, 167-179

277 Unusual Hysteroscopic Situations: Caesarean Niche and Retained Placental Tissue. **2020**, 193-203

276 Endometrial Histology and Safety on Non-Oral Routes of Hormone Therapy for Perimenopausal/Early Menopausal Women: Transdermal Estrogens and Vaginal Micronized Progesterone. **2020**,

275 Anatomy and Physiology of the Uterus. **2020**, 6-19


274 Indications for Hysteroscopy. **2020**, 83-95

273	Complications of Hysteroscopic Surgery. 2020 , 109-117		
272	Hysteroscopic Endometrial Polypectomy. 2020 , 118-129		
271	Infrastructure and Instrumentation for Hysteroscopy. 2020 , 20-35		
270	Hysteroscopic Management of Fibroids. 2020 , 144-157		
269	Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. 2020 , 30, 1331-1339		4
268	Endometrial Ablation. 2020 , 130-143		
267	Risk of occult atypical hyperplasia or cancer in women with nonatypical endometrial hyperplasia. 2020 , 46, 2505		1
266	Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. 2020 , 9, CD012658		8
265	Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. <i>Cancer</i> , 2020 , 126, 2775-2783	6.4	10
264	Endometrial development during the transition to menopause: preliminary associations with follicular dynamics. 2020 , 23, 288-297		2
263	Interventions to improve insulin resistance for the prevention of endometrial cancer. 2020 ,		0
262	Atlas of Hysteroscopy. 2020 ,		1
261	Dietary supplementation with spray-dried porcine plasma has prebiotic effects on gut microbiota in mice. 2020 , 10, 2926		13
260	Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. 2020 , 223, 103.e1-103.e13		17
259	Gynecological Pathology. 2020 , 1049-1521		
258	Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer. 2020 , 12,		7
257	Co-relation of endometrial thickness by transvaginal sonogram with histopathology pattern in abnormal uterine bleeding: a study from South India. 2020 , 9, 1416		
256	Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. 2021 , 224, 191.e1-191.e15		27

255	Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. 2021 , 253, 119-128	10
254	Nulliparity and postmenopausal status are independent factors of malignancy potential of endometrial intraepithelial neoplasia in polyps. 2021 , 152, 433-438	1
253	Uterine Epithelial Neoplasia. 2021 , 113-130	
252	International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Non-proliferative and Proliferative Lesions of the Non-human Primate (). 2021 , 34, 1S-182S	2
251	Molecular Pathology and Clinicopathological Significance of Endometrial Carcinoma. 2021 , 115-131	
250	Fundamentals of Gynecologic Ultrasound. 2021 , 251-270	
249	ANORMAL UTERİN KANAMASI OLAN OLGULARDA ULTRASONOGRAFİK BULGULAR ve HİSTOPATOLOJİK SONUÇLARI.	
248	Atypical Endometrial Hyperplasia, Low-grade: "Much ADO About Nothing". 2021 , 45, 988-996	1
247	Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. 2021 , 254, 20-30	2
246	A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women. 2021 , 22, 983-989	2
245	Endometrial hyperplasia: without atypia and with atypia. 2021 , 23, 18-24	0
244	Fertility-Sparing Treatment for Atypical Endometrial Hyperplasia and Endometrial Cancer: A Cochrane Systematic Review Protocol. 2021 , 38, 2717-2731	2
243	Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer. 2021 , 161, 152-159	7
242	Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer. 2021 , 13,	2
241	Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?. 2021 , 36, 100732	3
240	Non-atypical endometrial hyperplasia: risk factors for occult endometrial atypia and malignancy in patients managed with hysterectomy. 2021 , 64, 300-308	1
239	COMPARISON OF ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA & WHO CLASSIFIED ENDOMETRIAL HYPERPLASIA IN PREDICTING THE RISK OF PROGRESSION TO ENDOMETRIAL CARCINOMA. 2021 , 59-61	
238	Guizhi Fuling Capsule ameliorates endometrial hyperplasia through promoting p62-Keap1-NRF2-mediated ferroptosis. 2021 , 274, 114064	7

237	Near-Infrared Fluorescent Agent for Screening of Endometrial Cancer and Precancerous Lesions. 2021 , 11, 713583		
236	[Endometrial biopsy and curettage histoseminar. Cas n'3 and 4]. 2021 , 41, 361-365		
235	An Epidemiological Assessment of Endometrial Carcinoma Including Demographics and Histopathological Correlation, from a Tertiary Care Teaching Hospital in South India. 2021 , 8, 2751-2756		
234	ENDOMETRIAL BIOPSIES PATTERNS AMONG WOMEN ATTENDING MOI TEACHING AND REFERRAL HOSPITAL, KENYA. 2021 , 180-181		
233	Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia. 2021 , 19, 118		2
232	Comparison of endometrial cancer risk in patients with endometrial precancerous lesions: WHO 1994 vs EIN classification. 2021 , 1-4		
231	The clinical importance of polyp size measurement through two-dimensional saline infusion sonohysterography prior to hysteroscopic resection in predicting premalignant and malignant endometrial lesions. 2021 ,		0
230	Risk of More Advanced Lesions at Hysterectomy after Initial Diagnosis of Non-Atypical Endometrial Hyperplasia in Patients with Postmenopausal Bleeding and Oral Anticoagulant Treatment. 2021 , 57,		
229	Reliable Identification of Endometrial Precancers Through Combined Pax2, β Catenin, and Pten Immunohistochemistry. 2021 ,		0
228	Malignant diseases of the uterus: Endometrial Hyperplasia, Endometrial Carcinoma, Sarcoma: Diagnosis and Management. 2022 , 691-706.e5		
227	Lymphotoxin- β 804A polymorphism and the presence of simple endometrial hyperplasia in Egyptian women. 2021 , 8, 180-188		
226	Endometrial cancer. Management of high risk and recurrence including the tamoxifen controversy. <i>Cancer</i> , 1995 , 76, 2044-2052	6.4	2
225	Oral and intrauterine progestogens for atypical endometrial hyperplasia. 2018 , 12, CD009458		9
224	Endometrial Hyperplasia, Endometrial Intraepithelial Carcinoma, and Epithelial Cytoplasmic Change. 2005 , 178-207		5
223	Hormonal heterogeneity of endometrial cancer. 2008 , 630, 166-88		16
222	Endometrial Precancer. 2009 , 189-230		1
221	Precursor Lesions of Endometrial Carcinoma. 2011 , 359-391		11
220	Epidemiology of endometrial cancer. 1989 , 49, 1-21		5

219	Endometrial Hyperplasia and Neoplasia. 1989 , 333-353	4
218	Endometrial Hyperplasia and Metaplasia. 1987 , 322-337	7
217	Endometrial Carcinoma. 1987 , 338-372	23
216	Endometrial Hyperplasia and Related Cellular Changes. 1994 , 411-437	25
215	Endometrial Carcinogenesis. 2007 , 73-90	1
214	Endometrial Carcinoma: Precursor Lesions and Molecular Profiles. 2017 , 3-18	1
213	Functional Disturbances. 2010 , 59-108	1
212	Endometrial Cancer Prevention. 2014 , 593-611	1
211	Endometrial carcinomas. 1992 , 85, 1-34	3
210	Female reproductive system. 2011 , 1399-1657	1
209	Neoplastic Diseases of the Uterus. 2013 , 713-730	2
208	Cancer of the Endometrium. 2008 , 1793-1825	4
207	Hyperplasias of the Endometrium. 2004 , 249-257	3
206	Benign endometrial hyperplasia and EIN. 2009 , 367-391	4
205	Cytology of the body of the uterus. 2010 , 689-719	12
204	MRI of the Female Pelvis. 2005 , 269-342	2
203	Endometrial Cancer. 2000 , 916-931	6
202	Endometrial Neoplasia. 2009 , 233-259	2

201	Cancer of the Endometrium. 2010 , 1026-1051	0
200	Preinvasive Endometrial Neoplasia. 2011 , 457-489	3
199	Adenocarcinoma, Carcinosarcoma, and Other Epithelial Tumors of the Endometrium. 2011 , 517-581	2
198	The Female Genital Tract. 2010 , 1005-1063	31
197	Endometrial hyperplasia in infertile women undergoing IVF/ICSI: A retrospective cross-sectional study. 2020 , 49, 101780	4
196	HYSTEROSCOPY AND ADENOCARCINOMA. 1995 , 22, 573-579	19
195	Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. 1996 , 20, 1331-45	260
194	Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. 1998 , 22, 1012-9	224
193	A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. 1999 , 23, 1102-8	189
192	Indications for hysterectomy: have they changed?. 1997 , 40, 878-85	15
191	Bleeding problems and treatment. 1998 , 41, 928-39	11
190	The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment. 1998 , 53, 429-38	12
189	Decreased Expression of the Actin-Binding Protein Gelsolin in Endometrial and Ovarian Adenocarcinomas. 1998 , 6, 30-34	7
188	Management of endometrial precancers. 2012 , 120, 1160-75	130
187	Diagnosis of premalignant endometrial disease. 2002 , 55, 326-31	74
186	 2019 , 73-80	2
185	Hysteroscopic view with targeted biopsy in the assessment of endometrial carcinoma. What is the rate of underestimated diagnosis? The results of a multicenter Italian trial. 2020 , 17,	2
184	The value of MRI in management of endometrial hyperplasia with atypia. 2020 , 18, 34	3

183	Safety after extended repeated use of ulipristal acetate for uterine fibroids. 2017 , 12, e0173523	44
182	"Epidemiología de la Menopausia en Colombia: Estudio cooperativo". 1994 , 45, 20-27	2
181	Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. 2017 , 8, 68530-68541	5
180	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. 2015 , 6, 1327-39	42
179	Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study. 2020 , 31, e51	4
178	Astragalus root induces ovarian βoxidation and suppresses estrogen-dependent uterine proliferation. 2018 , 18, 5198-5206	4
177	Endometrial Assessment: When is it Necessary?. 2014 , 6, 21-5	7
176	Addition of power Doppler to grey scale transvaginal ultrasonography for improving the prediction of endometrial pathology in perimenopausal women with abnormal uterine bleeding. 2018 , 148, 302-308	3
175	Vascular markers CD31, CD34, actin, VEGFB, and VEGFR2, are prognostic markers for malignant development in benign endometrial polyps. 2012 , 02, 18-26	2
174	Does Preoperative Diagnosis of Endometrial Hyperplasia Necessitate Intraoperative Frozen Section Consultation?. 2016 , 33, 657-661	5
173	The endometrium. 2007 , 131, 372-82	21
172	Accuracy of frozen sections for intraoperative diagnosis of complex atypical endometrial hyperplasia. 2012 , 13, 1953-6	13
171	Endometrial Intraepithelial Neoplasia (EIN) in endometrial biopsy specimens categorized by the 1994 World Health Organization classification for endometrial hyperplasia. 2013 , 14, 5935-9	5
170	Which endometrial pathologies need intraoperative frozen sections?. 2013 , 14, 6121-5	12
169	Utility of frozen section pathology with endometrial pre-malignant lesions. 2014 , 15, 6053-7	5
168	Fertility-Sparing Treatment of Patients with Endometrial Cancer: A Review of the Literature. 2021 , 10,	1
167	Cancer of the corpus uteri: 2021 update. 2021 , 155 Suppl 1, 45-60	14
166	Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. 2021 , 339, 521-530	0

- 165 Endometrium. **2000**, 93-107
- 164 Pregnancy and Female Reproductive Disorders. **2000**, 921-931
- 163 HRT and Risk of Endometrial Cancer. **2000**, 591-606
- 162 Benign Gynecologic Disorders in the Elderly. **2001**, 817-833 1
- 161 Endometriumhyperplasie. **2001**, 531-542
- 160 Gynecology. **2001**, 1923-1943
- 159 Menopause and Hormone Replacement Therapy. **2002**, 417-474
- 158 Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium. **2003**, 21, 565-84 1
- 157 Uterine Cancer. **2003**, 531-543
- 156 ??????????????????????. **2004**, 22, 27-30 1
- 155 Prevention of Gynecologic Malignancies. **2004**, 883-919
- 154 Endometriumkarzinom. **2004**, 1073-1093
- 153 Pathology of Uterine Cancers. **2004**, 209-231 2
- 152 L'expression immunohistochimique de l'antigène PTEN : Un nouvel outil diagnostique dans les n'oplasies d'butantes de l'endom'etre. **2004**, 188, 415-429
- 151 Pathology of Endometrial Hyperplasia and Carcinoma. **2004**, 93-147
- 150 Steroid Hormone Receptors in the Normal Endometrium and in Endometrial Cancer. **2004**, 53-77
- 149 Molecular Genetics of Uterine Malignancies. **2004**, 1-33
- 148 Objective Biomarkers in Endometrioid-Type Endometrial Carcinogenesis. **2005**, 463-470

147 Carcinogenesis and the role of hormones. **2005**, 303-315

146 Estrogens, progestogens and the endometrium. **2005**, 105-116

145 Screening in Endometrial Cancer. **2005**, 13-29

144 Uterus and Fallopian Tube. **2006**, 1019-1067

143 Endometriumkarzinom. **2006**, 4559-4596

142 Gynäkologische Tumoren. **2006**, 419-483

141 Neoplastic Diseases of the Uterus. **2007**, 813-837

140 Clinical Trials in Postmenopausal Hormone Therapy. **2007**, 863-874

139 Mammakarzinom und gynäkologische Malignome. **2007**, 745-832

138 Erkrankungen des Uterus. **2008**, 423-505

137 Gynecology. **2008**, 2197-2216

136 Analysis of suspicious endometrial cytology-By a new criteria based on architectural atypia-. **2008**, 47, 249-254

135 Endometrial Hyperplasia and Carcinoma. **2008**, 161-193

134 Malignancy. **2008**, 832-848

133 Abnormal Uterine Bleeding During the Perimenopause. **2008**, 13-41

132 Performance Characteristics of Endometrial Cytology in a Hysterectomy-Controlled Environment. **2009**, 25-38

131 Polycystic Ovarian Syndrome and Gynaecological Cancer. **2009**, 155-165

130 Endometriose. **2009**, 561-578

- 129 Extracolonic Tumors. **2010**, 311-333
- 128 Diagnostic criteria of the endometrial cytology based on the cytoarchitecture of tissue fragments. **2010**, 49, 297-305
- 127 Endometrial Hyperplasia: Diagnosis and Management. 368-369
- 126 Uterus and Fallopian Tube. **2011**, 1343-1396
- 125 Gynecologic Malignancies in the Elderly. **2011**, 1101-1116
- 124 Irregular Bleeding during the Menopause Transition. 153-165
- 123 International Internet-based assessment of observer variability for diagnostically challenging endometrial biopsies. **2011**, 135, 464-70 7
- 122 Endometrial Cancer. 329-359
- 121 Endometrial Cancer. **2012**, 1215-1239
- 120 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 119 Pathology of Gynecologic Cancer. **2013**, 21-38
- 118 Surgical Considerations in Colorectal Endometriosis. **2013**, 569-577
- 117 Risk Factors Associated with Premalignant and Malignant Endometrial Polyps. **2013**, 19, 74 1
- 116 Endometrial Cancer. 1
- 115 Uterine Cancer. **2014**, 1575-1591.e4
- 114 Pathology. **1990**, 23-58
- 113 Abnormal Bleeding in the Climacteric. **1990**, 17, 409-425 6
- 112 The Uterine Corpus. **1992**, 263-278

111 Myomäre et endomäre. **1994**, 350-355

110 Prueba de estímulo con un progesténo para detección de pacientes menopáusicas en riesgo de desarrollar o tener patologā endometrial oculta. **1994**, 45, 35-40

109 Die Vaginalsonographie in der Postmenopause zur Endometriumdiagnostik. **1996**, 99-105

108 Weibliches Genitale. **1997**, 1-131

107 Gynecologic Cancers. **1997**, 317-335

106 Endometriumkarzinom. **1997**, 1129-1152

105 Abnormal Endometrial Biopsy: Pathology and Management. **1998**, 51-63

104 Maligne Tumoren des Corpus uteri. **1998**, 187-242

103 Korpuskarzinom. **1999**, 96-104

102 Diagnosis and Management of Postmenopausal Bleeding. **2015**, 1-7

2

101 Diseases of the Endometrium. **2015**, 107-123

100 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

99 Precancerous Lesions of Endometrioid Adenocarcinoma. **2016**, 125-149

98 Pathology of the Uterine Corpus. **2016**, 1-18

97 Uterus and Fallopian Tube. **2016**, 1491-1550

96 Endometrial Hyperplasia. **2016**, 1-15

95 Management of Abnormal Uterine Bleeding: Later Reproductive Years. **2016**, 1-12

94 Tactics of the management of patients with atypical endometrial hyperplasia. **2016**, 3, 188-192

2

- 93 Endometrial Hyperplasia. **2017**, 877-891 1
- 92 Management of Abnormal Uterine Bleeding: Later Reproductive Years. **2017**, 415-426
- 91 Gynkologische Tumoren. **2017**, 827-864
- 90 Management of Abnormal Uterine Bleeding: Later Reproductive Years. **2017**, 1-12
- 89 Diagnosis and Management of Postmenopausal Bleeding. **2017**, 509-515 1
- 88 Pathology of the Uterine Corpus. **2017**, 1041-1058
- 87 Erkrankungen des Uterus. **2017**, 381-451
- 86 A STUDY OF DYSFUNCTIONAL UTERINE BLEEDING- CLINICAL FACTORS AND ENDOMETRIAL HISTOLOGY. **2017**, 6, 1494-1497
- 85 Endometrial Hyperplasia. **2018**, 261-267
- 84 Obesity and Endometrial Cancer Precursors. **2018**, 63-71
- 83 Heterogeneity of the Precursor Lesions of Endometrial Carcinoma, According to the Histologic Subtype. **2018**, 27-36
- 82 Endometrial Thickness as a Predictor of Endometrial Hyperplasia in Infertile Patients with Polycystic Ovary Syndrome. **2018**, 08, 92-104 1
- 81 Problems associated with laparoscopic or abdominal hysterectomy for atypical endometrial hyperplasia. **2018**, 34, 184-187
- 80 Pathology of Endometrium: Benign Lesions, Preneoplastic Lesions and Carcinomas. **2019**, 187-236
- 79 Endometrial Cancer Prevention. **2019**, 653-676
- 78 Hysteroscopy Techniques and Treatment Settings. **2020**, 57-71
- 77 Diagnostic and Operative Hysteroscopy. **2020**, 1
- 76 Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview. **2021**, 22, 9

75	Atypical endometrial hyperplasia in a 35-year-old woman: A case report and literature review. 2021 , 9, 9629-9634	
74	Endometrial Glandular Neoplasia. 2020 , 333-406	
73	Risk factors of progression to endometrial cancer in women with endometrial hyperplasia: A retrospective cohort study. 2020 , 15, e0243064	2
72	Prevalence of Coexisting Endometrial Carcinoma in Patients with Preoperative Diagnosis of Endometrial Hyperplasia with Atypia. 2020 , 7, 3180-3184	
71	Endometrial Hiperplazi ve Karsinomunda Nükleus Boyutunun Karşılaştırmalı Morfometrik Analizi. 591-601	
70	Endometrial Hyperplasia. 2020 , 117-123	
69	Loss of ten-eleven translocation 1 (TET1) expression as a diagnostic and prognostic biomarker of endometrial carcinoma. 2021 , 16, e0259330	4
68	Endometrium. 2002 , 287-303	
67	Uterine Malignancies. 2006 , 937-959	
66	Introduction to Endometrial Cancer. 2007 , 51-72	
65	Pathophysiology and management of endometrial hyperplasia and carcinoma. 1990 , 153, 50-61	12
64	Endometrial sampling and general practice. 1997 , 47, 387-91	7
63	A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers. 1995 , 146, 501-8	82
62	Laminin production by human endometrial stromal cells relates to the cyclic and pathologic state of the endometrium. 1986 , 124, 384-91	44
61	Insights into endometrial serous carcinogenesis and progression. 2009 , 2, 411-32	35
60	Clinical and pathological correlations in endometrial pathology. 2015 , 8, 552-62	3
59	MORPHOLOGICAL PATTERN OF ENDOMETRIAL BIOPSIES IN SOUTHWESTERN NIGERIA. 2016 , 14, 103-109	1
58	Histopathological, Immunohistochemical and Therapeutical Assessment of Premalignant Endometrial Lesions in a Hospital Based Series of Cases. 2016 , 11, 115-121	1

57	Histopathology of women with non-uniform endometrial echogenicity and risk factors for atypical endometrial hyperplasia and carcinoma. 2021 , 13, 4500-4509	
56	Current state of fertility preservation for adolescent and young adult patients with gynecological cancer. 2021 , 27, 25	0
55	Prevention of endometrial hyperplasia without atypia in women of reproductive age. 2021 , 23, 454-458	
54	The Interaction of Menopause and Chronic Disease. 2022 , 91-120	1
53	Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia. 2022 , 111-122	
52	Endometrial hyperplasia as a risk factor of endometrial cancer.. 2022 , 1	5
51	Endometrial Hyperplasia without Atypia. 2022 , 103-110	
50	Historical Perspectives and Evolution of Menstrual Terminology. 2022 , 4,	0
49	Progesterone Actions and Resistance in Gynecological Disorders.. 2022 , 11,	6
48	Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.. 2022 , 23,	0
47	MicroRNAs as Predictors of Future Uterine Malignancy in Endometrial Hyperplasia without Atypia.. 2022 , 12,	0
46	Improving the diagnosis of endometrial hyperplasia using computerized analysis and immunohistochemical biomarkers.	
45	[Management of women with abnormal uterine bleeding: clinical practice guidelines of the French National College of Gynecologists and Obstetricians (CNGOF)].. 2022 ,	0
44	Endometrial hyperplasia in pre-menopausal women: A systematic review of incidence, prevalence, and risk factors.. 2022 , 271, 158-171	1
43	Endometrial cancer.. 2022 , 399, 1412-1428	28
42	Endometrial Stromal Expression of ER, PR, and B-Catenin Toward Differentiating Hyperplasia Diagnoses. 2021 , 10668969211065110	
41	Menopausal Status Combined with Serum CA125 Level Significantly Predicted Concurrent Endometrial Cancer in Women Diagnosed with Atypical Endometrial Hyperplasia before Surgery .. 2021 , 12,	0
40	Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer After Fertility-Preserving Treatment: A Multicenter Retrospective Study.. 2021 , 11, 808881	

- 39 Histopathologic diagnosis of endometrial precancers: Updates and future directions.. **2021**, 0
- 38 Short-term treatment results of endometrial hyperplasia without atypia. 1-6
- 37 Risk of atypical hyperplasia and endometrial carcinoma after initial diagnosis of non-atypical endometrial hyperplasia: A long-term follow-up study.. **2022**, 17, e0266339 1
- 36 The uterine corpus. 2659-2725
- 35 Endometrial samples with roughly equal ratio of glands to stroma. 19-40
- 34 Gland-predominant lesions with ratio of glands to stroma greater than 1:1. 41-65
- 33 Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia.. **2022**, 2
- 32 Improving the Diagnosis of Endometrial Hyperplasia Using Computerized Analysis and Immunohistochemical Biomarkers. **2022**, 4, 0
- 31 Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR-223/GLUT4 and SNHG20/miR-4486/GLUT4 signaling.. **2022**, 26, 1
- 30 Evaluation of postmenopausal bleeding. 14-24
- 29 Part 1: MR of the female pelvis. 18-23 0
- 28 Histopathological pattern of endometrial biopsies in patients with abnormal uterine bleeding in a tertiary referral hospital in Jordan. **2022**, 42, 204-213
- 27 A practical guide to the evaluation of benign endometrial conditions in biopsy and curettage material. **2022**,
- 26 Analysis of Factors Associated With Recurrence of Early-Stage Endometrial Carcinoma and Atypical Endometrial Hyperplasia in Infertile Women After In Vitro Fertilization Treatment. 12, 0
- 25 A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes. 13,
- 24 Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis. **2022**, 51, 102432
- 23 Insulin-Like Growth Factors, Insulin-Like Growth Factor-Binding Proteins, and Endometrial Cancer in Postmenopausal Women: Results from a U.S. Case-Control Study. **2004**, 13, 607-612 9
- 22 Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma. 0

21	Epithelial Tumors and Precursors, Type 1. 2022 , 1-15	0
20	Variants of in situ carcinoma of the endometrium: Clear cell and Gastrointestinal types, with a review of the literature. 2022 , 101078	0
19	Endometrial Cancer. 1-12	0
18	Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. 2023 , 104-124.e5	0
17	DYSMENORRHEA AND DYSFUNCTIONAL UTERINE BLEEDING. 1997 , 24, 161-178	1
16	Endometrial Hyperplasia. 2022 , Publish Ahead of Print,	0
15	Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia?. 2023 , 168, 107-113	0
14	Incidence of endometrial carcinoma in patients with endometrial intraepithelial neoplasia versus atypical endometrial polyp. <i>ijgc-2022-003991</i>	1
13	Endometrial Cancer. 2022 , 247-278	0
12	Endometrial Hyperplasia. 2023 , 1-19	0
11	Supplementation with d-chiro-inositol in women. 2023 , 175-195	0
10	Pathology of the endometrium and the clinical and diagnostic value of the glycodelin. 2023 , 23, 53	0
9	MOLECULAR MECHANISMS OF RESISTANCE OF ENDOMETRIAL HYPERPLASIA TO PROGESTAGEN THERAPY. 2023 , 433-439	0
8	Automated Prognostic Assessment of Endometrial Hyperplasia for Progression Risk Evaluation Using Artificial Intelligence. 2023 , 36, 100116	0
7	Diagnosis and Management of Postmenopausal Bleeding. 2023 , 1-7	0
6	Ecatenin, Pax2, and Pten Panel Identifies Precancers Among Histologically Subdiagnostic Endometrial Lesions. 2023 , 47, 618-629	0
5	Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea-based cohort study.	0
4	Human chorionic gonadotropin expression in endometrial hyperplasia and endometrial carcinoma: could it be a new marker?. <i>ijgc-2023-004279</i>	0

- 3 Fertility-Sparing Treatment and Assisted Reproductive Technology in Patients with Endometrial Carcinoma and Endometrial Hyperplasia: Pregnancy Outcomes after Embryo Transfer. **2023**, 15, 2123 ○
- 2 Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia. **2023**, 141, 979-987 ○
- 1 Association of Urinary Levels of Estrogens and Estrogen Metabolites with the Occurrence and Development of Endometrial Hyperplasia Among Premenopausal Women. ○